<SEC-DOCUMENT>0001193125-25-316216.txt : 20251211
<SEC-HEADER>0001193125-25-316216.hdr.sgml : 20251211
<ACCEPTANCE-DATETIME>20251211171716
ACCESSION NUMBER:		0001193125-25-316216
CONFORMED SUBMISSION TYPE:	424B8
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20251211
DATE AS OF CHANGE:		20251211

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alaunos Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001107421
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				841475642
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B8
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-291002
		FILM NUMBER:		251565796

	BUSINESS ADDRESS:	
		STREET 1:		501 E LAS OLAS BLVD
		STREET 2:		SUITE 300
		CITY:			FORT LAUDERDALE
		STATE:			FL
		ZIP:			33301
		BUSINESS PHONE:		(346) 355-4099

	MAIL ADDRESS:	
		STREET 1:		501 E LAS OLAS BLVD
		STREET 2:		SUITE 300
		CITY:			FORT LAUDERDALE
		STATE:			FL
		ZIP:			33301

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZIOPHARM ONCOLOGY INC
		DATE OF NAME CHANGE:	20050919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EASYWEB INC
		DATE OF NAME CHANGE:	20010213
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B8
<SEQUENCE>1
<FILENAME>d19490d424b8.htm
<DESCRIPTION>424B8
<TEXT>
<HTML><HEAD>
<TITLE>424B8</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed pursuant to Rule 424(b)(8)<BR>Registration No. 333-291002 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g19490g03a37.jpg" ALT="LOGO" STYLE="width:3.95909in;height:0.94091in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Up to 327,740 Shares of Common Stock </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman">This prospectus relates to the potential resale from time to time by Mast Hill Fund, L.P. (&#8220;Mast Hill&#8221; or the &#8220;Selling Stockholder&#8221;),
at prices and on terms that will be determined at the time of any such offering, of up to 327,740 shares of our common stock, par value $0.001 per share, which includes (1)&nbsp;up to 247,840 shares of our common stock (the &#8220;Purchase
Shares&#8221;) that may be issued to Mast Hill Fund, L.P. (&#8220;Mast Hill&#8221;) from time to time pursuant to the Equity Purchase Agreement, dated as of May&nbsp;19, 2025 (the &#8220;Purchase Agreement&#8221;), and (2)&nbsp;up to 79,900 shares
of our common stock, upon the exercise of the common stock purchase warrant (as amended, the &#8220;Warrant&#8221;) issued to Mast Hill under the Purchase Agreement (the &#8220;Warrant Shares&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman">Under the Purchase Agreement, we may elect to sell common stock to Mast Hill in an aggregate amount up to $25,000,000, over a period of up to 24&nbsp;months
commencing on the Commencement Date (as defined in the Purchase Agreement) and after satisfaction of other conditions in the Purchase Agreement. The five-year Warrant is immediately exercisable and has an initial exercise price per share of $4.00.
The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events
affecting the common stock and anti-dilution adjustments. The Purchase Shares and the Warrant Shares being registered under this prospectus are being registered in accordance with our obligations under the Registration Rights Agreement entered into
in connection with the Purchase Agreement. See &#8220;<I>The Equity Financing</I>&#8221; for a description of the Purchase Agreement and Warrant and see &#8220;<I>Selling Stockholder</I>&#8221; for additional information regarding the Selling
Stockholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman">Under the applicable rules of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;), in no event may we issue to the Selling Stockholder
shares of our common stock representing more than 19.99% of the total number of shares of common stock outstanding as of the date of the Purchase Agreement, unless (i)&nbsp;we obtain the approval of the issuance of such shares by our stockholders in
accordance with the applicable Nasdaq rules or (ii)&nbsp;or unless certain exceptions apply, such as if the securities were sold at or above the price paid under the Purchase Agreement for an &#8220;at market&#8221; issuance under Nasdaq rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman">We are not selling any securities under this prospectus and will not receive any of the proceeds from the sale of the shares of our common stock by the
Selling Stockholder. However, we may receive up to an aggregate of $25&nbsp;million in proceeds from the sale of our common stock to the Selling Stockholder pursuant to the Purchase Agreement and up to $319,600 in proceeds if the Selling Stockholder
exercises the Common Stock Purchase Warrant at $4.00 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman">The Selling Stockholder may offer, sell or distribute all or a portion of the shares of
our common stock acquired under the Purchase Agreement and hereby registered publicly or through private transactions at prevailing market prices or at negotiated prices. The actual proceeds from the Selling Stockholder may be less than this amount
depending on the number of shares of our common stock sold and the price at which the shares of our common stock are sold. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman">We will bear all costs,
expenses and fees in connection with the registration of the shares of our common stock, including with regard to compliance with state securities or &#8220;blue sky&#8221; laws. The timing and amount of any sales are within the sole discretion of
the Selling Stockholder. The Selling Stockholder is an underwriter under the Securities Act with respect to the resale of shares held by it. Although the Selling Stockholder is obligated to purchase shares of our common stock under the terms and
subject to the conditions and limitations of the Purchase Agreement to the extent we choose to sell such shares of our common stock to it (subject to certain conditions), there can be no assurances that we will choose to sell any shares of our
common stock to the Selling Stockholder, or that the Selling Stockholder will sell any or all of the shares of our common stock, if any, purchased under the Purchase Agreement pursuant to this prospectus. The Selling Stockholder will bear all
commissions and discounts, if any, attributable to its sale of shares of our common stock. See &#8220;<I>Plan of Distribution</I>.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman">Our common
stock is listed on The Nasdaq Capital Market under the symbol &#8220;TRCT.&#8221; On December&nbsp;10, 2025, the last reported sale price of our common stock on The Nasdaq Capital Market was $4.31 per share. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#8220;<A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312525245483/d19490ds1.htm#tx19490_3"></A></B><B><I><A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312525245483/d19490ds1.htm#tx19490_3" >Risk
Factors</A></I></B><B><A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312525245483/d19490ds1.htm#tx19490_3" ></A>&#8221; beginning on page 11 of this prospectus, and under similar headings in any amendment or supplement to this
prospectus or in any other documents incorporated by reference into this prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman"><B>NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE
SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is being filed pursuant to Rule&nbsp;424(b)(8) under the Securities Act of 1933, as amended, to provide the final, clean prospectus following
the automatic effectiveness of the registration statement on November&nbsp;10, 2025 (20&nbsp;calendar days after filing on October&nbsp;21, 2025). </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus dated December&nbsp;11, 2025 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx19490_1">About This Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx19490_2">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx19490_3">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx19490_4">Cautionary Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx19490_5">The Equity Financing</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx19490_6">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx19490_7">Market Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx19490_8">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx19490_9">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx19490_10">The Selling Stockholder</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx19490_11">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx19490_12">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx19490_13">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx19490_14">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx19490_15">Where You Can Find Additional Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx19490_16">Incorporation of Certain Information by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx19490_1"></A>ABOUT&nbsp;THIS&nbsp;PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The registration statement we filed with the Securities and Exchange Commission, or the SEC, includes exhibits that provide more detail of the matters
discussed in this prospectus. You should read this prospectus, the related exhibits filed with the SEC, and the documents incorporated by reference herein before making your investment decision. You should rely only on the information provided in
this prospectus and the documents incorporated by reference herein or any amendment thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should not assume that the information contained in this
prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference herein or therein is correct on any date subsequent to the date of the document incorporated
by reference, even though this prospectus is delivered, or securities are sold, on a later date. This prospectus contains or incorporates by reference summaries of certain provisions contained in some of the documents described herein, but reference
is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been or will be filed or have been or will be
incorporated by reference as exhibits to the registration statement of which this prospectus forms a part, and you may obtain copies of those documents as described in this prospectus under the heading &#8220;<I>Where You Can Find More
Information</I>.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should rely only on the information that we have included or incorporated by reference in this prospectus. Neither we nor the
Selling Stockholder has authorized any other person to provide you with different information. If anyone provides you with additional, different or inconsistent information, you should not rely on it. This prospectus is not an offer to sell these
securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise
indicated, information contained in or incorporated by reference into this prospectus concerning our business and the industry and markets in which we operate, including with respect to our business prospects, our market position and opportunity,
and the competitive landscape, is based on information from our management&#8217;s estimates, as well as from industry publications, surveys, and studies conducted by third parties. Our management&#8217;s estimates are derived from publicly
available information, their knowledge of our business and industry, and assumptions based on such information and knowledge, which they believe to be reasonable. In addition, while we believe that information contained in the industry publications,
surveys, and studies has been obtained from reliable sources, we have not independently verified any of the data contained in these third-party sources, and the accuracy and completeness of the information contained in these sources is not
guaranteed. Although we are not aware of any misstatements regarding the market and industry data presented in this prospectus and the documents incorporated herein by reference, these estimates involve risks and uncertainties and are subject to
change based on various factors, including those discussed under the heading &#8220;Risk Factors&#8221; in this prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus, including in our
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on March&nbsp;31, 2025, as amended on April&nbsp;30, 2025, and our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and Current Reports on Form <FONT
STYLE="white-space:nowrap">8-K.</FONT> Accordingly, you should not place undue reliance on this information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx19490_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights certain information about us, this offering, and information contained elsewhere in this prospectus and in the documents we
incorporate by reference. This summary is not complete and does not contain all of the information that you should consider before making an investment decision. To fully understand this offering and its consequences to you, you should read this
entire prospectus carefully, including the factors described under the heading &#8220;Risk Factors&#8221; in this prospectus beginning on page&nbsp;18, in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on March&nbsp;31,
2025, as amended on April&nbsp;30, 2025, our Quarterly Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q,</FONT> Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and the financial statements and all other information
incorporated by reference in this prospectus. When used in this prospectus, except where the context otherwise requires, the terms the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Alaunos,&#8221; or similar
terms refer to Alaunos Therapeutics, Inc. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;10, 2024, we announced our continued progress and evaluation of our internally developed small molecule oral obesity program. The aim of this
program is to develop a drug for obesity with a differentiated profile relative to currently marketed and in development oral and injectable products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
have also operated as a clinical-stage oncology-focused cell therapy company developing <FONT STYLE="white-space:nowrap">adoptive&nbsp;TCR-T&nbsp;cell</FONT> therapy, designed to treat multiple solid tumor types in large cancer patient populations
with unmet clinical needs. On August&nbsp;14, 2023, we announced a strategic reprioritization of our business and wind down of <FONT STYLE="white-space:nowrap">our&nbsp;TCR-T&nbsp;Library</FONT> Phase 1/2 Trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the reprioritization, we reduced our workforce during the third and fourth quarters of 2023, and we continue working to reduce costs in
order to extend our cash runway. We continue to explore strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not generated any product revenue and have incurred significant net losses in each year since our inception. For the six months ended June&nbsp;30,
2025, we had a net loss of $2.1&nbsp;million, and as of June&nbsp;30, 2025, we have incurred approximately $922.6&nbsp;million of accumulated deficit since our inception in 2003. We expect to continue to incur significant operating expenditures and
net losses for the foreseeable future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Small Molecule Oral Obesity Program </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are advancing our internally developed, preclinical small molecule program for the treatment of obesity and related metabolic disorders. This program
focuses on discovering and developing novel, orally administered therapeutics with the potential for a differentiated and complementary profile compared to currently available therapies. While other pipeline therapies for obesity explore alternative
hormonal pathways such as amylin or <FONT STYLE="white-space:nowrap">dual&nbsp;GIP/GLP-1&nbsp;receptor</FONT> agonism, our approach is focused on <FONT STYLE="white-space:nowrap">a&nbsp;non-hormonal&nbsp;mechanism</FONT> of action. The program seeks
to develop an oral therapeutic with the potential to address certain limitations of existing hormonal therapies, including the potential for preservation of lean muscle mass during weight loss and an improved tolerability profile. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the fourth quarter of 2024, we engaged a contract development and manufacturing organization (CDMO) to synthesize active pharmaceutical ingredients
(APIs) for our product candidates. We have since initiated a portfolio of preclinical studies to evaluate these product candidates. Initial in vitro characterization studies conducted by a contract research organization (CRO) encountered
methodological issues related to the assay, which prevented the generation of conclusive data. This CRO has since completed the necessary method development to resolve these issues, and these studies are being repeated. In parallel, we have
conducted an in vivo pharmacokinetic (PK) study of our product candidate ALN1003 and have initiated a pilot in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vivo&nbsp;proof-of-concept&nbsp;(PoC)</FONT></FONT> study of ALN1003 in
a diet-induced obesity (DIO) mouse model. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collectively, these ongoing studies are designed to assess our candidates&#8217; effects on key biological
pathways implicated in metabolic disease, including receptor binding, lipid accumulation, food consumption, weight loss, and the expression of genes related to thermogenesis and energy expenditure. We anticipate initial data from these ongoing in
vitro and in vivo studies will be available no later than the fourth quarter of 2025. These data are intended to inform the future development strategy for our product candidates and guide indication selection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The advancement of this program is subject to numerous risks and uncertainties inherent in early-stage drug development. Subject to favorable data from these
preclinical studies and our ability to secure additional capital, we plan to advance a selected development candidate into formal investigational new drug (IND)-enabling studies. We intend to actively explore strategic financing and collaboration
opportunities to fund the continued development of this program. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Obesity Market </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Obesity remains one of the most pressing public health challenges globally, with rates continuing to rise across many regions, particularly in the United
States, Europe, and parts of Asia. It is closely linked to a range of comorbid conditions, including type 2 diabetes, cardiovascular diseases, and certain cancers, which exacerbates the overall healthcare burden. The obesity market is seeing
increased attention, driven by growing awareness, better treatment options, and emerging scientific breakthroughs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The global obesity market is
experiencing rapid growth. Globally, the market size for branded obesity drugs was $6&nbsp;billion in 2023 and is estimated that it will reach $105.0&nbsp;billion by 2030. This growth is fueled by the rising obesity prevalence, evolving patient
demographics, and increasing demand for effective weight-management solutions. The shift toward more personalized treatments and the need for long-term weight management are key drivers of this growth. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The current treatment landscape for obesity consists of a combination of lifestyle interventions, pharmaceuticals, and surgical options. Lifestyle
interventions&#8212;dietary changes and physical activity&#8212;are the first-line treatment for most individuals, but many struggle to achieve and maintain significant weight loss through these methods alone. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Traditional weight-loss medications (e.g., OrlistatTM) are still used, though their side effects and modest results have limited their appeal. Newer drugs, <FONT
STYLE="white-space:nowrap">like&nbsp;GLP-1&nbsp;receptor</FONT> agonists (e.g., OzempicTM, WegovyTM), are quickly becoming the gold standard in the market. These drugs, which mimic the action of gut hormones to promote satiety and reduce appetite,
have shown remarkable efficacy in clinical trials and are significantly improving patient outcomes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The success
<FONT STYLE="white-space:nowrap">of&nbsp;GLP-1s&nbsp;has</FONT> led to a surge in interest from both pharmaceutical companies and patients. However, issues such as high cost, insurance reimbursement, and potential long-term side effects remain areas
of concern. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The future of the obesity market is promising, with new therapies, enhanced patient targeting, and continued scientific breakthroughs on the
horizon. As the global obesity epidemic continues to grow, demand for more effective and affordable treatments will likely continue to rise. However, success will depend on overcoming challenges related to cost, access, and patient adherence.
Advancements in personalized <FONT STYLE="white-space:nowrap">medicine,&nbsp;non-invasive&nbsp;treatments,</FONT> and innovative drug mechanisms will shape the next phase of the obesity treatment landscape. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The obesity market today is vibrant and expanding, but still in need of accessible, scalable, and sustainable solutions to effectively manage this complex and
widespread health issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Historical Development and Achievements in Cancer Therapeutics </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We previously focused on <FONT STYLE="white-space:nowrap">developing&nbsp;TCR-T&nbsp;cell</FONT> therapies for solid tumors using <FONT
STYLE="white-space:nowrap">our&nbsp;non-viral&nbsp;Sleeping</FONT> Beauty platform and hunTR<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&nbsp;TCR discovery platform. Key milestones included: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">TCR-T&nbsp;Library</FONT> Phase 1/2 Trial (2022-2023): Treated eight patients
with solid tumors (e.g., pancreatic, colorectal, lung). The trial <FONT STYLE="white-space:nowrap">showed&nbsp;TCR-T&nbsp;cells</FONT> were well-tolerated, with no dose-limiting toxicities or neurotoxicity. Cytokine release syndrome <FONT
STYLE="white-space:nowrap">(grades&nbsp;1-3)&nbsp;resolved</FONT> with standard care. <FONT STYLE="white-space:nowrap">One&nbsp;non-small&nbsp;cell</FONT> lung cancer patient achieved a partial response (13% response rate), and six others had stable
disease (87% disease control rate), <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">establishing&nbsp;proof-of-concept&nbsp;that</FONT></FONT> Sleeping <FONT STYLE="white-space:nowrap">Beauty&nbsp;TCR-T&nbsp;cells</FONT> can result
in objective clinical responses an recognize established tumors<I>&nbsp;in vivo</I>. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hunTR<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&nbsp;Platform: Identified proprietary TCRs
targeting driver mutations (KRAS, TP53, others) and various HLAs, expanding the TCR library for potential patient treatment. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August
2023, however, due to substantial development costs and a challenging financing environment, we announced a strategic reprioritization, including the wind-down of <FONT STYLE="white-space:nowrap">our&nbsp;TCR-T&nbsp;Library</FONT> Phase 1/2 Trial
and cessation of further clinical development <FONT STYLE="white-space:nowrap">of&nbsp;TCR-T&nbsp;programs.</FONT> This involved: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Workforce reductions (approximately 95% by the end of 2023) and cost-cutting measures to extend cash runway.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Termination of key licenses and agreements: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">NCI patent license (effective December&nbsp;26, 2023), after internally developing proprietary TCRs via hunTR
targeting similar mutations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">NCI CRADA (effective October&nbsp;13, 2023). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Precigen exclusive license (fully terminated October&nbsp;4, 2024, following an amendment in April 2023 that
eliminated royalty/milestone obligations). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">Trial&nbsp;close-out&nbsp;activities,</FONT> including internal processes, with
ongoing costs for <FONT STYLE="white-space:nowrap">long-term&nbsp;follow-up&nbsp;and</FONT> regulatory obligations. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result,
research and development expenses related to cancer programs have significantly declined, from $11.7&nbsp;million for the six months ended June&nbsp;30, 2023, to $0.3&nbsp;million for the same period in 2025, reflecting the shift away from active
oncology development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are actively exploring strategic alternatives to maximize stockholder value, including but not limited to acquisitions, mergers,
reverse mergers, asset sales, strategic partnerships, or capital raises. These may involve monetizing cancer-related assets, such <FONT STYLE="white-space:nowrap">as&nbsp;out-licensing&nbsp;the</FONT> TCR library or hunTR platform. We have engaged
Cantor Fitzgerald&nbsp;&amp; Co. as a strategic advisor for this process. However, there are no assurances that any transaction will be consummated, and failure to do so could lead to further operational curtailment or dissolution. Our primary focus
has shifted to our preclinical small-molecule obesity and metabolic disorder program, with ongoing preclinical<I>&nbsp;in vitro</I>&nbsp;and<I>&nbsp;in vivo</I><I></I>&nbsp;studies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selected Risks Related to our Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business is
subject to numerous risks, including risks that may prevent us from achieving our business objectives or may adversely affect our business, financial condition, results of operations, cash flows and prospects that you should consider before making
an investment decision. Some of the more significant risks and uncertainties relating to an investment in our company are listed below. These risks are more fully described in the section titled &#8220;<I>Risk Factors</I>&#8221; in this prospectus
and in Part I, Item 1A of our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;for</FONT> the year ended December&nbsp;31, 2024, and in Part II, Item 1A of our Quarterly Reports on
<FONT STYLE="white-space:nowrap">Form&nbsp;10-Q&nbsp;for</FONT> the fiscal quarters ended March&nbsp;31, 2025 and June&nbsp;30, 2025, which are incorporated by reference into this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also
impair our business operations. You should be able to bear a complete loss of your investment. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our strategic reprioritization may not be successful, may not yield the desired results and we may be
unsuccessful in identifying and implementing any strategic transaction. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If a strategic transaction is not consummated, our board of directors (&#8220;<I>Board</I>&#8221;) may decide to
pursue a dissolution and liquidation. In such an event, the amount of cash available for distribution to our stockholders will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved for
commitments and contingent liabilities. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may require substantial additional financial resources to continue as a going concern, including through the
strategic review process, and if we raise additional funds it may affect the value of your investment in our common stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our ability to consummate a strategic transaction depends on our ability to retain our current employees and
consultants. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our stock price has been, and may continue to be, volatile. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our decreasing cash reserves had resulted in our shareholder equity falling below $2,500,000 as required by
Nasdaq Listing Rule 5550(b)(1), which resulted in our receipt of a delisting notice from Nasdaq in April of 2025. While we have reestablished compliance with the listing rule based on our Quarterly Report on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> for the period ended June&nbsp;30, 2025, evidencing stockholders&#8217; equity of $3.66&nbsp;million, we remain at risk of future <FONT STYLE="white-space:nowrap">non-compliance</FONT> if our cash
reserves continue to decline or if we face unexpected financial challenges, which could lead to further delisting actions by Nasdaq. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have identified a material weakness and failed to maintain an effective internal control environment, which
may result in material misstatements of our financial statements or have a material adverse effect on our business or stock price. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our small molecule obesity program is early stage and may encounter issues with manufacturing of the active
pharmaceutical ingredient(s) or with the in vitro or in vivo studies that could preclude clinical trials or be costly to address with respect to time or money. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For our small molecule oral obesity program or should we resume development of
<FONT STYLE="white-space:nowrap">our&nbsp;TCR-T&nbsp;product</FONT> candidates, any candidate for which we obtain marketing approval could be subject to post-marketing restrictions or withdrawal from the market and we may be subject to significant
penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, when and if any of them are approved. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For our small molecule oral obesity program, or should we resume development of
<FONT STYLE="white-space:nowrap">our&nbsp;TCR-T&nbsp;product</FONT> candidates, if we fail to obtain the necessary U.S. or worldwide regulatory approvals to commercialize any product candidate, our business will suffer materially.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may not be able to commercialize, generate significant revenues from, or attain profitability from our small
molecule oral obesity program or, should we resume development of, <FONT STYLE="white-space:nowrap">our&nbsp;TCR-T&nbsp;product</FONT> candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The termination of <FONT STYLE="white-space:nowrap">our&nbsp;TCR-T&nbsp;related</FONT> licenses and research and
development agreements could limit our ability to resume <FONT STYLE="white-space:nowrap">our&nbsp;TCR-T&nbsp;clinical</FONT> trial or begin new clinical trials. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may become involved in litigation, including securities class action litigation, that could divert
management&#8217;s attention and harm our business, and insurance coverage may not be sufficient to cover all costs and damages. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent
their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following any potential marketing approval. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The gene transfer vectors from the Sleeping Beauty system used to manufacture
<FONT STYLE="white-space:nowrap">our&nbsp;TCR-T&nbsp;product</FONT> candidates may incorrectly modify the genetic material of a patient&#8217;s T cells, potentially triggering the development of a new cancer or other adverse events.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable either to create sales, marketing and distribution capabilities or enter into agreements with
third parties to perform these functions, we will be unable to commercialize our product candidates successfully. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If physicians and patients do not accept and use our product candidates, once approved, or if we do not obtain
coverage and adequate reimbursement from payors, our ability to generate revenue from sales of our products will be materially and adversely impaired. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our small molecule and immuno-oncology product candidates may face competition in the future from generics or
biosimilars and/or new technologies and our pending patent applications may not be granted, further limiting our ability to compete with other companies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we fail to adequately protect or enforce our intellectual property rights or secure rights to patents of
others, the value of our intellectual property rights would diminish and our ability to successfully commercialize our products may be materially impaired. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Third-party claims of intellectual property infringement would require us to spend significant time and money and
could prevent us from developing or commercializing our products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have and will rely significantly on information technology and any failure, inadequacy, interruption or
security lapse of that technology or loss of data, including any cybersecurity incidents, could compromise sensitive information related to our business, prevent us from accessing critical information or expose us to liability which could harm our
ability to operate our business effectively and materially and adversely affect our business and reputation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Anti-takeover provisions in our charter documents and under Delaware law may make an acquisition of us, which may
be beneficial to our stockholders, more difficult. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive
forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Because we do not expect to pay dividends, you will not realize any income from an investment in our common stock
unless and until you sell your shares at a profit. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our ability to use net operating loss carryforwards and research tax credits to reduce future tax payments may be
limited or restricted. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The exercise of outstanding warrants, and issuance of equity awards may have a dilutive effect on our stock, and
negatively and materially impact the price of our common stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our principal stockholders, executive officers and directors have substantial control over the Company, which may
prevent you and other stockholders from influencing significant corporate decisions and may significantly harm the market price of our common stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are a &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to smaller
reporting companies may make our common stock less attractive to investors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other risks described from time to time in periodic and current reports that we file with the SEC.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Mast Hill Transaction </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
May&nbsp;19, 2025, we entered into an equity purchase agreement (the &#8220;Purchase Agreement&#8221;) and a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with Mast Hill Fund, L.P., a Delaware limited
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
partnership (&#8220;Mast Hill&#8221;). Pursuant to the Purchase Agreement, Mast Hill has committed to purchase up to $25,000,000 of the Company&#8217;s newly issued shares common stock, par value
$0.001 per share (the &#8220;common stock&#8221;), from time to time during the term of the Purchase Agreement, subject to certain limitations and conditions (the &#8220;Mast Hill Offering&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Purchase Agreement initially precludes us from issuing and selling more than 327,740 shares of our common stock, including the Warrant Shares, which
number equals 19.99% of our common stock issued and outstanding as of May&nbsp;18, 2025, unless we obtain stockholder approval to issue additional shares, or unless certain exceptions apply. One such exception applies where the average price paid
for all shares of common stock issued under the Purchase Agreement (including both Purchase Shares and the Warrant Shares) is equal to or greater than $2.40, which is a price equal to the lower of (i)&nbsp;the Nasdaq Official Closing Price
immediately preceding the execution of the Purchase Agreement and (ii)&nbsp;the average Nasdaq Official Closing Price of our common stock for the five trading days immediately preceding the execution of the Purchase Agreement, as calculated in
accordance with the rules of Nasdaq, such that the sales of such common stock to the Selling Stockholder would not count toward such limit because they are &#8220;at market&#8221; under applicable stock exchange rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, a beneficial ownership limitation in the agreement initially limits us from directing Mast Hill to purchase shares of common stock if such
purchases would result in Mast Hill beneficially owning more than 4.99% of the then-outstanding shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the terms and subject to
the satisfaction of the conditions set forth in the Purchase Agreement, the Company has the right, but not the obligation, to sell to Mast Hill, and Mast Hill is obligated to purchase, up to $25,000,000 of common stock, at a purchase price per share
equal to the lesser of (i) 97% of the lowest VWAP of the Company&#8217;s common stock, as listed on Nasdaq, on any trading day during the period beginning on the put date and continuing through the date that is two trading days immediately following
the clearing date associated with the applicable put notice (such two trading day period is the &#8220;<I>Valuation Period</I>&#8221;), or (ii) 102% of the lowest traded price of the Company&#8217;s common stock, as listed on Nasdaq, on any trading
day during the Valuation Period, on such date on which the purchase price is calculated in accordance with the terms of the Purchase Agreement. Such sales of common stock by the Company, if any, are subject to certain limitations set forth in the
Purchase Agreement, and may occur from time to time, at the Company&#8217;s sole discretion, over a period of up <FONT STYLE="white-space:nowrap">to&nbsp;24-months,&nbsp;commencing</FONT> on the date of the Purchase Agreement, including the
effectiveness of a registration statement registering under the Securities Act, the resale by Mast Hill of shares of common stock that may be issued by the Company to Mast Hill under the Purchase Agreement and upon the exercise of the Warrant (as
defined below). The Company has agreed to file such registration statement with the Securities and Exchange Commission within 60 days from the date of execution of the Purchase Agreement and the Registration Rights Agreement. We will control the
timing and amount of any such sales of common stock to Mast Hill. Actual sales of shares of common stock to Mast Hill will depend on a variety of factors to be determined by us from time to time, including, among other things, market conditions, the
trading price of our common stock, and determinations by us as to the appropriate sources of funding for the Company and our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have the
right to terminate the Purchase Agreement at any time after its commencement, at no cost or penalty, upon prior written notice to Mast Hill, except during any Valuation Period or at any time that Mast Hill holds any shares of common stock purchased
by Mast Hill under the Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for Mast Hill&#8217;s commitment to purchase shares of common stock in accordance with the
Purchase Agreement, the Company has issued to Mast Hill a warrant to purchase 79,900 shares of common stock (as amended, the &#8220;Warrant&#8221;) concurrently with the execution of the Purchase Agreement. The Warrant is immediately exercisable and
will expire on the fifth anniversary of the original issuance date. The Warrant has an initial exercise price per share of $4.00. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in
the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock and anti-dilution adjustments. On June&nbsp;9, 2025, the Company entered into an Amendment
No.&nbsp;1 to the common stock Purchase Warrant Issued on May&nbsp;19, 2025 (the &#8220;Warrant Amendment&#8221;) with Mast Hill. The Warrant Amendment (i)&nbsp;added a floor price </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
equal to $0.57 per share, with respect to certain adjustment to the exercise price of the Warrant in the event of any Dilutive Issuance (as defined in the Warrant), issuance of Variable Price (as
defined in the Warrant) securities and certain other events set forth in Section&nbsp;2(e) of the Warrant; (ii)&nbsp;removed the requirement to adjust the number of shares of common stock issuable upon exercise of the Warrant in the event of a
Dilutive Issuance, a Variable Price adjustment or under Section&nbsp;2(e) of the Warrant; and (iii)&nbsp;removed certain rights of the Warrant holder in connection with fundamental transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds, if any, from the Mast Hill Offering for working capital and general corporate purposes, including sales and marketing
activities, product development and capital expenditures. We may also use a portion of the net proceeds to acquire or invest in complementary businesses, products and technologies. The Purchase Agreement and the Registration Rights Agreement contain
customary representations, warranties, conditions and indemnification obligations of the parties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We originally incorporated in Colorado in September 1998 (under the name Net Escapes, Inc.) and later changed our name to &#8220;EasyWeb, Inc.&#8221; in
February 1999. <FONT STYLE="white-space:nowrap">We&nbsp;re-incorporated&nbsp;in</FONT> Delaware on May&nbsp;16, 2005 under the same name. On September&nbsp;13, 2005, we completed a &#8220;reverse&#8221; acquisition of privately held Ziopharm, Inc.,
a Delaware corporation. To effect this transaction, we caused ZIO Acquisition Corp., our wholly-owned subsidiary, to merge with and into Ziopharm, Inc., with Ziopharm, Inc. surviving as our wholly owned subsidiary. Following the merger, we caused
Ziopharm, Inc. to merge with and into us and we changed our name to &#8220;Ziopharm Oncology, Inc.&#8221; As a result, Ziopharm, Inc. became the registrant with the Securities and Exchange Commission, or the SEC, and the historical financial
statements of Ziopharm, Inc. became our historical financial statements. On January&nbsp;25, 2022, we filed a Certificate of Amendment to our Amended and Restated Certificate of Incorporation with the Delaware Secretary of State to change our name
to Alaunos Therapeutics, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at 501 E. Las Olas Blvd., Suite 300, Fort Lauderdale, FL 33301, and our
telephone number is <FONT STYLE="white-space:nowrap">(346)&nbsp;355-4099.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our corporate website address is www.alaunos.com. We make available on
or through our website our periodic reports that we file with the SEC. Information contained in, or accessible through, our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual
reference only. The contents of our website are not incorporated by reference into this document and shall not be deemed &#8220;filed&#8221; under the Securities Exchange Act of 1934, as amended (the &#8220;<I>Exchange Act</I>&#8221;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE OFFERING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following summary contains basic information about this offering. The summary is not intended to be complete. You should read the full text and more
specific details contained elsewhere in this prospectus. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of common stock offering by the Selling Stockholder </P></TD>
<TD>327,740 shares of our common stock, par value $0.001 per share, which includes (1)&nbsp;up to 247,840 Purchase Shares that may be issued to Mast Hill from time to time pursuant to the Purchase Agreement, and (2)&nbsp;up to 79,900 Warrant Shares,
upon the exercise of the Warrant issued to Mast Hill under the Purchase Agreement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of common stock outstanding immediately prior to this offering </P></TD>
<TD>2,321,829&nbsp;shares (as of October&nbsp;20, 2025) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Terms of the offering </P></TD>
<TD>The Selling Stockholder will determine when and how it will dispose of any shares of our common stock that are registered under this prospectus for resale. See &#8220;Plan of Distribution.&#8221; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We will not receive any of the proceeds from the sale of shares of our common stock offered by the Selling Stockholder. However, we may receive up to an aggregate of $25&nbsp;million in proceeds from the sale of our common stock to the Selling
Stockholder pursuant to the Purchase Agreement and up to $319,600 in proceeds if the Selling Stockholder exercises the Common Stock Purchase Warrant at $4.00 per share. However, the actual proceeds may be less than this amount depending on the
number of shares of our common stock sold and the price at which the shares of our common stock are sold. We intend to use any net proceeds that we receive under the Purchase Agreement for working capital and other general corporate purposes.
However, as of the date of this prospectus, we cannot specify with certainty all of the particular uses, and the respective amounts we may allocate to those uses, for any net proceeds we receive. See &#8220;<I>Use of Proceeds.</I>&#8221;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>Investing in our securities is highly speculative and involves a high degree of risk. You should carefully consider the information set forth in the &#8220;Risk Factors&#8221; section beginning on page&nbsp;11 of this prospectus, and in the
documents incorporated herein and therein by reference. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Capital Market symbol </P></TD>
<TD>Our shares of common stock are traded on The Nasdaq Capital Market under the symbol &#8220;TCRT&#8221;. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on 2,321,829&nbsp;shares of our common stock outstanding as of
October&nbsp;20, 2025, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">136,327 shares of Common Stock issuable upon the exercise of outstanding warrants to purchase our Common Stock,
with a weighted average exercise price of $7.52&nbsp;per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">229,128&nbsp;shares of Common Stock issuable upon exercise of outstanding stock options under our equity
incentive plan, with a weighted average exercise price of $29.04 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">217,390 shares of Common Stock issuable upon the conversion of the Company&#8217;s Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Convertible Preferred Stock; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">227,170 shares of Common Stock issuable upon the conversion of the
<FONT STYLE="white-space:nowrap">Company&#8217;s&nbsp;Series&nbsp;A-2&nbsp;Convertible</FONT> Preferred Stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise
indicated, all information in this prospectus assumes no exercise of the outstanding Series <FONT STYLE="white-space:nowrap">A-1</FONT> and Series A-2 Convertible Preferred Stock, stock options or warrants described above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx19490_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing in our securities involves a high degree of risk. This prospectus does not describe all of those risks. You should consider the risk factors
described in this prospectus, as well as those described under the caption &#8220;Risk Factors&#8221; in the documents incorporated by reference herein, including our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on
March&nbsp;31, 2025, as amended on April&nbsp;30, 2025, and our subsequent Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC, together
with other information contained in or incorporated by reference in this prospectus, the information and documents incorporated by reference herein. The occurrence of any of the events or developments described below could materially and adversely
affect our business, financial condition, results of operations and prospects. In such an event, the market price of our common stock could decline and you may lose all or part of your investment. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our common stock and this Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>It is not possible to predict the actual number of shares we will sell under the Purchase Agreement to Mast Hill, or the actual gross proceeds resulting
from those sales. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;19, 2025, we entered into the Purchase Agreement with Mast Hill, pursuant to which Mast Hill committed to purchase
up to $25,000,000 in shares of our common stock, subject to certain limitations and conditions set forth in the Purchase Agreement. We generally have the right to control the timing and amount of any sales of our shares of common stock to Mast Hill
under the Purchase Agreement, although we are unable to control the market price of the common stock at the time such shares are sold or the purchase price per share that Mast Hill will pay for such shares. Our decision to sell shares of common
stock under the Purchase Agreement, if any, to Mast Hill will depend upon market conditions, the trading price of the common stock, determinations by us as to the appropriate sources of funding for our operations, and other factors to be determined
by us. We may ultimately decide to sell to Mast Hill all, some, or none of the Purchase Shares that may be available for us to sell pursuant to the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, although the Purchase Agreement provides that we may sell up to an aggregate of $25,000,000 of Purchase Shares to Mast Hill, we are precluded from
issuing and selling more than 327,740 shares of our common stock (including the Warrant Shares), which number equals 19.99% of the number of shares of our common stock issued and outstanding as of May&nbsp;19, 2025 (the &#8220;Exchange Cap&#8221;),
unless we obtain stockholder approval to issue shares of our common stock in excess of the Exchange Cap or unless another exception applies such as &#8220;at market&#8221; issuances. If, after the Commencement Date, we elect to sell to Mast Hill all
of the Purchase Shares permitted under the Purchase Agreement, the actual gross proceeds from the sale of all such Mast Hill may be substantially less than the $25,000,000 total commitment in light of the Exchange Cap limitation, which could
materially adversely affect our liquidity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, because the purchase price per share to be paid by Mast Hill for the Purchase Shares that we may
elect to sell to them under the Purchase Agreement, if any, will fluctuate based on the market prices of our common stock during the three consecutive trading day period immediately following the exercise date for such purchase made pursuant to the
Purchase Agreement, it is not possible for us to predict, as of the date of this prospectus and prior to any such sales, the number of shares of common stock that we will sell to Mast Hill thereunder, if any, the purchase price per share that Mast
Hill will pay for such shares, or the aggregate gross proceeds that we will receive from those purchases, if any. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Selling Stockholder will pay
less than the then-prevailing market price for our common stock, which could cause the price of our common stock to decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purchase price of
our common stock to be sold to the Selling Stockholder under the Purchase Agreement is derived from the market price of our common stock on Nasdaq. Shares to be sold to the Selling Stockholder pursuant to the Purchase Agreement will be purchased at
a discounted price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the terms and subject to the satisfaction of the conditions set forth in the Purchase Agreement, the
Company has the right, but not the obligation, to sell to Mast Hill, and Mast Hill is obligated to purchase, up to $25,000,000 of common stock, at a purchase price per share equal to the lesser of (i) 97% of the lowest VWAP of the Company&#8217;s
common stock, as listed on Nasdaq, on any trading day during the period beginning on the put date and continuing through the date that is two trading days immediately following the clearing date associated with the applicable put notice (such two
trading day period is the &#8220;Valuation Period&#8221;), or (ii) 102% of the lowest traded price of the Company&#8217;s common stock, as listed on Nasdaq, on any trading day during the Valuation Period, on such date on which the purchase price is
calculated in accordance with the terms of the Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of this pricing structure, the Selling Stockholder may sell the shares
they receive immediately after receipt of such shares, which could cause the price of our common stock to decrease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Management has broad discretion
as to the use of proceeds from our sale of the Purchase Shares and Warrant Shares under the Purchase Agreement, if any, and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your
investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management has broad discretion over the use of proceeds from the sale of any shares of common stock to Mast Hill pursuant to the
Purchase Agreement and from the exercise of the Warrant. You may not agree with our decisions, and our use of the proceeds may not yield any return on your investment. Our failure to effectively apply the net proceeds from such sale could compromise
our ability to pursue our business strategy, and we might not be able to yield a significant return, if any, on our investment of these net proceeds. In addition, the net proceeds from such sale may not be sufficient for our anticipated uses, and we
may need additional resources to progress our service offerings to the stage we expect. You will not have the opportunity to influence our decisions on how to use our net proceeds from any sale of shares of common stock to Mast Hill pursuant to the
Purchase Agreement and from the exercise of the Warrant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The sale or issuance of the securities registered for resale hereunder, or the perception
that such sales may occur, could cause the price of our common stock to decrease. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The sale of shares of our common stock to Mast Hill as Purchase
Shares under the Purchase Agreement will be at our sole discretion from time to time, commencing after the satisfaction of certain conditions set forth in the Purchase Agreement until May&nbsp;19, 2027. The purchase price for the Purchase Shares
that we may sell to Mast Hill under the Purchase Agreement will fluctuate based on the trading price of our common stock. Depending on market liquidity at the time, sales of such Purchase Shares may cause the trading price of our common stock to
decrease. We generally have the right to control the timing and amount of any future sales of Purchase Shares to Mast Hill. We may ultimately decide to sell to Mast Hill all, some or none of the Purchase Shares that may be available for us to sell
pursuant to the Purchase Agreement. If and when we do sell Purchase Shares to Mast Hill, after Mast Hill Mast Hill acquired the Purchase Shares, Mast Hill may resell all, some or none of those shares at any time or from time to time in its
discretion. Therefore, sales to Mast Hill by us could result in substantial dilution to the interests of other holders of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly,
our existing stockholders may experience substantial dilution as a result of the sale of shares of common stock pursuant to this prospectus. The sale of these securities in the public market, or the perception that holders of a large number of
securities intend to sell their securities, could reduce the market price of our common stock. However, the number of shares of our common stock ultimately offered for resale by the Buyers under this prospectus is dependent upon the number of shares
of common stock ultimately issued to the Buyers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot predict if and when the Selling Stockholder may sell such shares of the common stock in the
public markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the purchase price for the Purchase Shares under the Purchase Agreement may be below the current and/or then trading prices
of shares of our common stock or below the price at which our existing shareholders </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purchased our common stock. The Selling Stockholders may potentially make a significant profit with the resale of the securities depending on the trading price of our securities at the time of a
sale and the purchase price of such securities by them. While the Selling Stockholders may experience a positive rate of return based on the trading price of our securities, the existing holders of our common stock may not experience a similar rate
of return on the shares of common stock they purchased due to differences in the applicable purchase price and trading price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the sale of a
substantial number of shares of our common stock by the Selling Stockholder, or the anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might
otherwise wish to effect sales. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The terms of the Purchase Agreement limit the amount of shares of common stock we may issue to Mast Hill, which may
have an adverse effect on our liquidity. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Purchase Agreement includes restrictions on our ability to sell Purchase Shares to Mast Hill,
including, subject to specified limitations, if a sale would cause Mast Hill and its affiliates to beneficially own more than 4.99% of our issued and outstanding common stock. Accordingly, we cannot guarantee that we will be able to sell all
$25,000,000 shares of common stock under the Purchase Agreement. If we cannot sell the full amount of the shares that Mast Hill has committed to purchase because of these limitations, we may be required to utilize more costly and time-consuming
means of accessing the capital markets, which could materially adversely affect our liquidity and cash position. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may issue additional equity or
equity-linked securities in the future, which may result in additional dilution to you. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that significant additional capital will be
needed in the future to continue our planned operations. To the extent that we raise additional capital by issuing equity securities, including securities exercisable for or convertible into shares of our common stock, our existing
shareholders&#8217; ownership may experience substantial dilution, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common shareholder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Although our common stock is listed on the Nasdaq Capital Market, our shares are likely to be thinly traded for some time and an active market may never
develop. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although our common stock is listed on the Nasdaq Capital Market, it is likely that initially there will be a very limited trading
market for our common stock, and we cannot ensure that a robust trading market will ever develop or be sustained. Our shares of common stock may be thinly traded, and the price, if traded, may not reflect our actual or perceived value. There can be
no assurance that there will be an active market for our shares of common stock in the future. The market liquidity will be dependent on the perception of our operating business, competitive forces, state of the live stream and gaming industry,
growth rate and becoming cash flow profitable on a sustainable basis, among other things. We may, in the future, take certain steps, including utilizing investor awareness campaigns, press releases, road shows, and conferences to increase awareness
of our business and any steps that we might take to bring us to the awareness of investors may require we compensate financial public relations firms with cash and/or stock. There can be no assurance that there will be any awareness generated or the
results of any efforts will result in any impact on our trading volume. Consequently, investors may not be able to liquidate their investment or liquidate it at a price that reflects the value of the business and trading may be at an inflated price
relative to the performance of our company due to, among other things, availability of sellers of our shares. If a market should develop, the price may be highly volatile. Because there may be a low price for our shares of common stock, many
brokerage firms or clearing firms may not be willing to effect transactions in the securities or accept our shares for deposit in an account. Even if an investor finds a broker willing to effect a transaction in the shares of our common stock, the
combination of brokerage commissions, transfer fees, taxes, if any, and any other selling costs may exceed the selling price. Further, many lending institutions will not permit the use
<FONT STYLE="white-space:nowrap">of&nbsp;low-priced&nbsp;shares</FONT> of common stock as collateral for any loans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We received a notice from Nasdaq that our common stock may be delisted from trading on the Nasdaq
Capital Market if we fail to comply with the continued listing requirements, including the minimum bid price requirement. A delisting of our common stock is likely to reduce the liquidity of our common stock and may inhibit or preclude our ability
to raise additional financing. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are required to comply with certain Nasdaq continued listing requirements, including a minimum bid price for our
common stock, as well as a series of financial tests relating to stockholder equity, market value of listed securities and number of market makers and stockholders. If we fail to maintain compliance with any of those requirements, our common stock
could be delisted from Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our decreasing cash reserves has resulted in our shareholder equity falling below $2,500,000 as required by Nasdaq Listing
Rule 5550(b)(1), which resulted in our receipt of a delisting notice from Nasdaq in April of 2025. In our 2024 Annual Report, we reported stockholders&#8217; equity of $2,063,000. While we have reestablished compliance with the listing rule based on
our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the period ended June&nbsp;30, 2025, evidencing stockholders&#8217; equity of $3.66&nbsp;million, we remain at risk of future
<FONT STYLE="white-space:nowrap">non-compliance</FONT> if our cash reserves continue to decline or if we face unexpected financial challenges, which could lead to further delisting actions by Nasdaq. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our common stock is delisted by Nasdaq, it could lead to a number of negative implications, including an adverse effect on the price of our common stock,
deterring broker-dealers from making a market in or otherwise seeking or generating interest in our common stock, increased volatility in our common stock, reduced liquidity in our common stock, the loss of federal preemption of state securities
laws and greater difficulty in obtaining financing. Delisting could also cause a loss of confidence of our customers, collaborators, vendors, suppliers and employee, which could harm our business and future prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our common stock is delisted by Nasdaq, the price of our common stock may decline, and although our common stock may be eligible to trade on the OTC
Bulletin Board, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">another&nbsp;over-the-counter&nbsp;quotation</FONT></FONT> system, or on the pink sheets, an investor may find it more difficult to dispose of their common stock or
obtain accurate quotations as to the market value of our common stock. If our common stock is delisted from Nasdaq, trading in our securities may be subject to the SEC&#8217;s &#8220;penny stock&#8221; rules. These &#8220;penny stock&#8221; rules
will require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our common stock. The additional burdens imposed upon broker-dealers by
these requirements may discourage broker-dealers from recommending transactions in our securities, which could severely limit the liquidity of our securities and consequently adversely affect the market price for our securities. Furthermore, if our
common stock is delisted, we would expect it to have an adverse impact on our ability to consummate certain strategic alternatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, if our
common stock is delisted, we would incur additional costs under state blue sky laws in connection with any sales of our securities. These requirements could severely limit the market liquidity of our common stock and the ability of our stockholders
to sell our common stock in the secondary market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx19490_4"></A>CAUTIONARY NOTES REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and the documents incorporated by reference herein contain forward-looking statements that involve substantial risks and uncertainties. The
forward-looking statements are contained principally in the sections of this prospectus entitled &#8220;<I>Prospectus Summary</I>&#8221; and &#8220;<I>Risk Factors</I>,&#8221; as well as in those sections of our 2024 Annual Report and Quarterly
Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q&nbsp;entitled</FONT> &#8220;<I>Business</I>,&#8221; &#8220;<I>Risk Factors</I>,&#8221; and &#8220;<I>Management</I>&#8217;<I>s Discussion and Analysis of Financial Condition and Results of
Operations</I>,&#8221; as applicable, but are also contained elsewhere in this prospectus. In some cases, you can identify forward-looking statements by the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221;
&#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;objective,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221;
&#8220;potential,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; or &#8220;would,&#8221; or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown
risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe
that we have a reasonable basis for making each forward-looking statement contained in this prospectus, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future,
about which we cannot be certain. Forward-looking statements are subject to considerable risks and uncertainties, as well as other factors that may cause our actual results, levels of activity, performance or achievements to be materially different
from the information expressed or implied by these forward-looking statements, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully implement our strategic reprioritization or realize any or all of the anticipated
benefits once implemented; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to raise substantial additional capital to continue as a going concern and fund our planned
operations in the near term and our strategic reprioritization in the longer term; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully consummate any strategic transactions, including, but not limited to, an acquisition,
merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">estimates regarding our expenses, use of cash, cash runway, timing of future cash needs and anticipated capital
requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to license additional intellectual property to support our strategic reprioritization <FONT
STYLE="white-space:nowrap">or&nbsp;out-license&nbsp;our</FONT> intellectual property and to comply with our existing license agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to enter into partnerships or strategic collaboration agreements and our ability to achieve the
results and potential benefits contemplated from relationships with collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain collaborations and licenses; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectation of developments and projections relating to competition from other pharmaceutical and
biotechnology companies or our industry; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans relating to conducting future<I>&nbsp;in vitro</I>&nbsp;testing,<I>&nbsp;in vivo</I>&nbsp;efficacy
studies, <FONT STYLE="white-space:nowrap">and&nbsp;non-clinical&nbsp;and</FONT> investigational new drug <FONT STYLE="white-space:nowrap">or&nbsp;IND-enabling&nbsp;activities;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anticipated amount, timing and accounting of contract liabilities, milestones and other payments under
licensing, collaboration or acquisition agreements, research and development costs and other expenses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to remain listed on the Nasdaq Capital Market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intellectual property position, including the strength and enforceability of our intellectual property
rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other risks and uncertainties, including those described within the section entitled &#8220;<I>Risk
Factors</I>&#8221; in our 2024 Annual Report and 2025 Quarterly Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q,&nbsp;and</FONT> subsequent Quarterly Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q,&nbsp;which</FONT> risk
factors are incorporated herein by reference. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This list of factors that may affect future performance and the accuracy of forward-looking statements is
illustrative, but not exhaustive. New risk factors and uncertainties not described here or elsewhere in this prospectus, including in the section entitled &#8220;<I>Risk Factors</I>,&#8221; may emerge from time to time. Moreover, because we operate
in a competitive and rapidly changing environment, it is not possible for our management to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of
factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. The forward-looking statements are also subject to the risks and uncertainties specific to our Company, including but not
limited to the fact that we have only a limited operating history as a public company. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this prospectus may not occur, and actual results could differ
materially and adversely from those anticipated or implied in the forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should not rely upon forward-looking statements as
predictions of future events. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance and events and circumstances reflected in the
forward-looking statements will be achieved or occur. Moreover, neither we nor any other person assume responsibility for the accuracy and completeness of the forward-looking statements. Except as required by applicable law, including the securities
laws of the United States, we do not intend and do not undertake an obligation to update any of the forward-looking statements to conform these statements to actual results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should read this prospectus, the accompanying prospectus and the documents incorporated herein or therein and those documents filed as exhibits to the
registration statement, of which this prospectus is a part, with the understanding that our actual future results, levels of activity, performance and achievements may be materially different from what we expect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx19490_5"></A>THE EQUITY FINANCING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Description of the Purchase Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;19,
2025, we entered into the Purchase Agreement and the Registration Rights Agreement with Mast Hill pursuant to which we have the right, but not the obligation, to sell to Mast Hill up to $25,000,000 of shares of common stock (the &#8220;Total
Commitment&#8221; and shares of common stock sold pursuant to the Purchase Agreement, the &#8220;Purchase Shares&#8221;), subject to certain limitations and conditions set forth therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus covers the resale by Mast Hill of up to $594,816 of our common stock (up to 247,840 shares), all of which are shares of common stock that we
may sell to Mast Hill under the Purchase Agreement from time to time over <FONT STYLE="white-space:nowrap">the&nbsp;24-month&nbsp;period</FONT> from and after the date of the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a description of the material terms of the issuance and sale of securities pursuant to the Purchase Agreement. It does not purport to be
complete. This summary is subject to and is qualified by reference to all the provisions of the Purchase Agreement, the Registration Rights Agreement and the Warrant, including the definitions of certain terms used therein. We urge you to read these
documents because they, and not this description, define your rights as the investor thereunder. You may request copies of these agreements, and related ancillary documents, as set forth under the section titled &#8220;<I>Where You Can Find
Additional Information</I>.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for Mast Hill&#8217;s commitment to purchase shares of common stock in accordance with the Purchase
Agreement, the Company has issued to Mast Hill the Warrant to purchase 79,900 shares of common stock concurrently with the execution of the Purchase Agreement. The Warrant is immediately exercisable and will expire on the fifth anniversary of the
original issuance date. The Warrant has an initial exercise price per share of $4.00. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of certain stock dividends and
distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock and anti-dilution adjustments. We also agreed to reimburse Mast Hill for
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">certain&nbsp;out-of-pocket&nbsp;expenses</FONT></FONT> incurred in connection with the transactions contemplated under the Purchase Agreement (including its legal fees and expenses),
in an aggregate amount of approximately $17,500. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;9, 2025, the Company entered into the Warrant Amendment with Mast Hill. The Warrant
Amendment (i)&nbsp;added a floor price equal to $0.57 per share, with respect to certain adjustment to the exercise price of the Warrant in the event of any Dilutive Issuance (as defined in the Warrant), issuance of Variable Price (as defined in the
Warrant) securities and certain other events set forth in Section&nbsp;2(e) of the Warrant; (ii)&nbsp;removed the requirement to adjust the number of shares of common stock issuable upon exercise of the Warrant in the event of a Dilutive Issuance, a
Variable Price adjustment or under Section&nbsp;2(e) of the Warrant; and (iii)&nbsp;removed certain rights of the Warrant holder in connection with fundamental transactions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Purchase and Sale of Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the initial
satisfaction of the conditions to our right to commence sales of Purchase Shares to Mast Hill set forth in the Purchase Agreement (such event, the &#8220;Commencement&#8221;), we will have the right, but not the obligation, from time to time at our
sole discretion over <FONT STYLE="white-space:nowrap">the&nbsp;24-month&nbsp;period</FONT> from and after the date of the Purchase Agreement (the &#8220;Commencement Date&#8221;), subject to earlier termination as set forth in the Purchase
Agreement, to direct Mast Hill to make purchases of Purchase Shares, as further described in the Purchase Agreement (each, a &#8220;Purchase&#8221;) by delivering a Put Notice (as such term is defined in the Purchase Agreement) on any trading day
(the trading day during the Commitment Period that a Put Notice is deemed delivered is, the &#8220;Put Date&#8221;), so long as the lowest traded price of the common stock in the 10 trading days immediately preceding the Put Date exceeds $0.01 per
share. Such sales of common stock by the Company, if any, are subject to certain limitations set forth in the Purchase Agreement, including the effectiveness of a registration statement registering under the Securities Act, the resale by Mast Hill
of shares of common stock that may be issued by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company to Mast Hill under the Purchase Agreement and underlies upon the exercise of the Warrant. The Company has agreed to file such registration statement with the Securities and Exchange
Commission within 60&nbsp;days from the date of execution of the Purchase Agreement and the Registration Rights Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purchase price of the
Purchase Shares that we elect to sell to Mast Hill pursuant to a Purchase (the &#8220;Purchase Price&#8221;) will be the lesser of (i) 97% of the lowest VWAP of the Company&#8217;s common stock, as listed on Nasdaq, on any trading day during the
Valuation Period (such price, the &#8220;Market Price&#8221;), or (ii) 102% of the lowest traded price of the Company&#8217;s common stock, as listed on Nasdaq, on any trading day during the Valuation Period (such price, the &#8220;Market
Alternative Price&#8221;), on such date on which the Purchase Price is calculated in accordance with the terms of the Purchase Agreement. The Company may at its option specify a minimum share price with respect to the common stock (the
&#8220;Minimum Price&#8221;) in such Put Notice. If a Minimum Price is specified by the Company in the Put Notice and the common stock trades at a price per share that is less than the Minimum Price during the respective Valuation Period (the
&#8220;Minimum Price Trigger&#8221;), then the number of Purchase Shares with respect to such Purchase shall automatically be reduced to the number of Purchase Sharees sold by Mast Hill prior to the first time that the common stock traded below the
Minimum Price during the respective Valuation Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may direct Mast Hill, by its delivery of a Put Notice, to purchase Purchase Shares:
(i)&nbsp;in a minimum amount not less than $5,000 (calculated using 97% of the VWAP of the common stock, as reported on Nasdaq, on the trading date immediately preceding the applicable Put Date (the &#8220;Initial Purchase Price&#8221;) and
(ii)&nbsp;in a maximum amount up to the lesser of (a) $500,000 (calculated using the Initial Purchase Price) or (b) 20% of the average trading volume of the common stock, as reported on Nasdaq, during the five trading days immediately preceding the
applicable Put Date<I>&nbsp;multiplied</I>&nbsp;by the VWAP of the common stock as reported on Nasdaq on the trading date immediately preceding the applicable Put Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From and after Commencement, we will control the timing and amount of any sales of Purchase Shares to Mast Hill. Actual sales of Purchase Shares to Mast Hill
under the Purchase Agreement will depend on a variety of factors to be determined by us from time to time, including, market conditions, the trading price of the common stock, and determinations by us as to the appropriate sources of funding for our
operations. We may ultimately decide to sell to Mast Hill all, some, or none of the Purchase Shares that may be available for us to sell pursuant to the Purchase Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Beneficial Ownership Limitation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Purchase Agreement
prohibits us from directing Mast Hill to purchase any Purchase Shares if those shares, when aggregated with all other shares of our common stock then beneficially owned by Mast Hill (as calculated pursuant to Section&nbsp;13(d) of the Exchange Act,
and <FONT STYLE="white-space:nowrap">Rule&nbsp;13d-3&nbsp;thereunder)</FONT> would result in Mast Hill beneficially owning more than 4.99% of our issued and outstanding common stock (the &#8220;Beneficial Ownership Limitation&#8221;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exchange Cap </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under applicable Nasdaq rules, in no event
may we issue to Mast Hill under the Purchase Agreement more than 327,740 shares of our common stock (including the Warrant Shares), which number of shares equals the Exchange Cap, unless we obtain stockholder approval to issue shares of common stock
in excess of the Exchange Cap or unless another exception applies such as &#8220;at market&#8221; issuances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Proceeds </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because the purchase price per share to be paid by Mast Hill for the Purchase Shares that we may elect to sell under the Purchase Agreement, if any, will
fluctuate based on the market prices of our common stock during the Valuation Period for each Purchase made, as of the date of this prospectus it is not possible for us to predict the number of shares of common stock that we will sell to Mast Hill
thereunder, the actual purchase price per share to be paid by Mast Hill for such shares, or the actual gross proceeds to be raised by us from those sales, if any. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of October&nbsp;20, 2025, there were 2,321,829 shares of our common stock issued and outstanding, which
excludes both the Warrant Shares issuable to Mast Hill and the Purchase Shares we may, in our sole discretion, sell to Mast Hill from time to time from and after the date of the Purchase Agreement pursuant to the Purchase Agreement. Further,
although the Purchase Agreement provides that we may issue and sell up to an aggregate of $25,000,000 of Purchase Shares to Mast Hill, only 327,740 shares of our common stock (representing the maximum number of shares we may issue and sell under the
Purchase Agreement in light of the Exchange Cap limitation) may be sold to Mast Hill and are being registered for resale under this prospectus, which includes the Warrant Shares. If all of the shares offered hereunder were issued and outstanding as
of October&nbsp;20, 2025, such shares would represent approximately 12.37% of the total number of shares of our common stock outstanding as of October&nbsp;20, 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If, after the Commencement Date, we elect to sell to Mast Hill all of the Purchase Shares (in addition to the Warrant Shares) that are available for sale by
us to Mast Hill under the Purchase Agreement and that are being registered for resale under this prospectus, depending on the market prices of our common stock during the applicable Valuation Period for each Purchase made pursuant to the Purchase
Agreement, the actual gross proceeds to us from the sale of all such shares may be substantially less than the $25,000,000 Total Commitment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If it
becomes necessary for us to issue and sell to Mast Hill more shares of our common stock than are being registered for resale under this prospectus, we must first (i)&nbsp;obtain stockholder approval to issue shares of our common stock in excess of
the Exchange Cap in accordance with applicable Nasdaq rules, and (ii)&nbsp;file with the SEC one or more additional registration statements to register under the Securities Act the resale by Mast Hill of any such additional shares of our common
stock we wish to sell from time to time under the Purchase Agreement, which the SEC must declare effective, in each case before we may elect to sell any additional shares of our common stock to Mast Hill under the Purchase Agreement. Any issuance
and sale by us under the Purchase Agreement of a substantial amount of shares of our common stock in addition to the 327,740 shares being registered for resale hereunder could cause additional substantial dilution to our stockholders. The number of
shares of our common stock ultimately offered for sale by Mast Hill is dependent upon the number of Purchase Shares, if any, we ultimately sell to Mast Hill under the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proceeds from sales of Purchase Shares, if any, under the Purchase Agreement will depend on the frequency and prices at which we sell Purchase Shares to
Mast Hill. To the extent we sell Purchase Shares under the Purchase Agreement, we plan to use any proceeds therefrom for working capital and general corporate purposes, including sales and marketing activities, product development and capital
expenditures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conditions Precedent to Commencement and For Delivery of Purchase Notices </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our right to deliver Purchase Notices to Mast Hill under the Purchase Agreement, and Mast Hill&#8217;s obligation to accept Put Notices delivered by us, are
subject to (i)&nbsp;the initial satisfaction, at the Commencement, and (ii)&nbsp;the satisfaction, on the applicable Put Date for each Purchase after the Commencement Date, of the conditions precedent thereto set forth in the Purchase Agreement,
which conditions include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the accuracy in all material respects of our representations and warranties included in the Purchase Agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the registration statement that includes this prospectus (and any one or more additional registration statements
filed with the SEC that include shares of common stock that may be issued and sold by us to Mast Hill under the Purchase Agreement and upon exercise of the Warrant) shall continue to be effective under the Securities Act, and Mast Hill is able to
utilize this prospectus to resell all of the shares of common stock included in this prospectus (and included in any such additional prospectuses); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the SEC shall not have issued any stop order suspending the effectiveness of the registration statement that
includes this prospectus (or any one or more additional registration statements filed with the SEC that include shares of common stock that may be issued and sold by us to Mast Hill under the Purchase Agreement and upon exercise of the Warrant) or
prohibiting or suspending the use of this prospectus; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">both us and Mast Hill shall have performed, satisfied and complied in all material respects with all covenants,
agreements and conditions required by the Purchase Agreement to be performed, satisfied or complied with by such party; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trading in our common stock shall not have been suspended by the SEC, Nasdaq, or the Financial Industry
Regulatory Authority (&#8220;FINRA&#8221;), or otherwise halted for any reason, and our common stock shall have been approved for listing on and shall not have been delisted from Nasdaq; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there shall be the absence of any statute, rule, regulation, executive order, decree, ruling or injunction by any
court or governmental authority of competent jurisdiction that prohibits or directly and materially adversely affects the transactions contemplated by the Purchase Agreement, the Registration Rights Agreement or the Warrant (collectively, the
&#8220;<I>Transaction Documents</I>&#8221;), and no proceeding shall have been commenced that may have the effect of prohibiting or materially adversely affecting any of the transactions contemplated by the Transaction Documents;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">since the date of filing of the Company&#8217;s most recent filing required under the Securities Act and the
Exchange Act, no event that had or is reasonably likely to have a material adverse effect has occurred; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of Purchase Shares that Mast Hill is obligated to purchase under the Purchase Agreement, when
aggregated with all other shares of common stock then owned by Mast Hill beneficially or deemed beneficially owned by Mast Hill, shall not exceed the Beneficial Ownership Limitation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company shall not effect any sales of the Purchase Shares under the under the Purchase Agreement to the
extent that such issuance would exceed the Exchange Cap, unless the Company first obtains stockholder approval to issue shares of common stock in excess of the Exchange Cap in accordance with applicable Nasdaq listing rules; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company shall have no knowledge of any event more likely than not to have the effect of causing the
registration statement that includes this prospectus (or any one or more additional registration statements filed with the SEC that include shares of common stock that may be issued and sold by us to Mast Hill under the Purchase Agreement and upon
exercise of the Warrant) to be suspended or otherwise ineffective; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance of the Purchase Shares shall not violate the shareholder approval requirements of Nasdaq;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on the date of delivery of each Put Notice, Mast Hill shall have received the closing certificate executed by an
executive officer of the Company and to the effect that all the conditions to such closing shall have been satisfied as of the date of each such certificate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the common stock must be DWAC eligible and not subject to a &#8220;DTC chill&#8221;; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all reports, schedules, registrations, forms, statements, information and other documents required to have been
filed by the Company with the SEC pursuant to the reporting requirements of the Exchange Act shall have been filed with the SEC within the applicable time periods prescribed for such filings under the Exchange Act; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company shall have reserved the minimum number of shares of common stock required to be reserved for the Mast
Hill&#8217;s benefit pursuant to the Purchase Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lowest traded price of the common stock in the 10 trading days immediately preceding the respective Put Date
must exceed $0.01 per share; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings, voluntary or involuntary,
for relief under any bankruptcy law or any law for the relief of debtors shall not be instituted by or against the Company or any subsidiary of the Company, and the Company shall have no knowledge of any event more likely than not to have the effect
of causing such bankruptcy proceedings to arise. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Covenants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Purchase Agreement contains customary representations, warranties, covenants and indemnification obligations of the parties. The representations,
warranties and covenants contained in the Purchase Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the
contracting parties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Restrictions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no
restrictions on future financings, rights of first refusal, participation rights, penalties or liquidated damages in the Purchase Agreement, other than a prohibition on entering into certain &#8220;Equity Line of Credit&#8221; or &#8220;Variable
Rate Transactions,&#8221; as defined in the Purchase Agreement. Mast Hill has agreed not to cause, or engage in any manner whatsoever in, any direct or indirect short selling of our common stock during the term of the Purchase Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Termination </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Purchase Agreement will automatically
terminate upon the earliest of (i)&nbsp;the expiration of <FONT STYLE="white-space:nowrap">the&nbsp;24-month&nbsp;period</FONT> following the Commencement Date, (ii)&nbsp;Mast Hill&#8217;s purchase of the Purchase Shares equal to Total Commitment,
or (iii)&nbsp;the occurrence of certain other events set forth in the Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have the right to terminate the Purchase Agreement at any
time after Commencement, at no cost or penalty, upon prior written notice to Mast Hill, provided that Mast Hill no longer holds any Purchase Shares and such notice is not delivered during a Valuation Period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Existing Stockholders; Dilution </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All shares of common
stock registered in this offering which have been or may be issued or sold by us to Mast Hill under the Purchase Agreement are expected to be freely tradable. It is anticipated that shares of common stock registered in this offering may be issued
and sold by us to Mast Hill from time to time at our discretion over a period of up to 24 months commencing on the Commencement Date. The issuance of shares of our common stock to Mast Hill pursuant to the Purchase Agreement will not affect the
rights or privileges of our existing common stockholders, except that the economic and voting interests of each of our existing common stockholders will be diluted. Although the number of shares of our common stock that our existing stockholders own
will not decrease, the shares of our common stock owned by our existing stockholders will represent a smaller percentage of our total outstanding shares of common stock after any such issuance. There are substantial risks to our stockholders as a
result of the sale and issuance of common stock to Mast Hill under the Purchase Agreement. For additional information, refer to the sections of this prospectus titled &#8220;<I>Risk Factors</I>&#8221; and &#8220;<I>Dilution</I>.&#8221; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Effect of Performance of the Purchase Agreement on Our Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All 327,740 shares of common stock registered in this offering which have been or may be issued or sold by us to Mast Hill under the Purchase Agreement are
expected to be freely tradable. It is anticipated that Common Shares registered in this offering will be sold over a period starting on the date that the registration statement of which this prospectus is a part is declared effective and ending on
the first day of the month immediately following the 24 month anniversary of the execution date of the Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The sale by Mast Hill of a
significant amount of Common Shares registered in this offering at any given time could cause the market price of Common Shares to decline and to be highly volatile. Sales of common stock to Mast Hill, if any, will depend upon market conditions and
other factors to be determined by us. We may ultimately decide to sell to Mast Hill all, some or none of the additional Common Shares that may be available for us to sell pursuant to the Purchase Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If and when we do sell shares to Mast Hill, after Mast Hill has acquired the Common Shares, Mast Hill may
resell all, some or none of those Common Shares at any time or from time to time in its discretion. Therefore, sales to Mast Hill by us under the Purchase Agreement may result in substantial dilution to the interests of other holders of Common
Shares. In addition, if we sell a substantial number of Common Shares to Mast Hill under the Purchase Agreement, or if investors expect that we will do so, the actual sales of Common Shares or the mere existence of our arrangement with Mast Hill may
make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect such sales. However, we have the right to control the timing and amount of any additional sales
of Common Shares to Mast Hill and the Purchase Agreement may be terminated by us at any time at our discretion without any cost to us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx19490_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will not receive any of the proceeds from the sale of shares of our common stock offered by the Selling Stockholder. However, we may receive up to an
aggregate of $25&nbsp;million in proceeds from the sale of our common stock to the Selling Stockholder pursuant to the Purchase Agreement and up to $319,600 in proceeds if the Selling Stockholder exercises the Common Stock Purchase Warrant at $4.00
per share. However, the actual proceeds may be less than this amount depending on the number of shares of our common stock sold and the price at which the shares of our common stock are sold. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to use any net proceeds that we receive under the Purchase Agreement for working capital and other general corporate purposes, including sales and
marketing activities, product development and capital expenditures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also use a portion of the net proceeds from this offering to <FONT
STYLE="white-space:nowrap">in-license,</FONT> acquire or invest in complementary businesses, technologies, products or assets. Although we currently have no agreements, commitments or obligations to do so, we evaluate such opportunities and engage
in related discussions with third parties from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our expected use of the net proceeds from this offering represents our intentions based upon
our current plans and business conditions. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering or the amounts that we will actually
spend on the uses set forth above. The amounts and timing of our actual expenditures and the extent of our preclinical, clinical and future development activities may vary significantly depending on numerous factors, including the progress of our
development efforts, the status of and results from our planned clinical trials, our ability to take advantage of expedited programs or to obtain regulatory approval for product candidates, the timing and costs associated with the manufacture and
supply of product candidates for clinical development or commercialization and any unforeseen cash needs. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pending the uses described above, we plan to invest the net proceeds from this offering in short-term, interest-bearing obligations, investment-grade
instruments or other securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx19490_7"></A>MARKET INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;TCRT.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of October&nbsp;20, 2025, we had approximately 130 holders of record of our common stock, one of which was Cede&nbsp;&amp; Co., a nominee for Depository
Trust Company, or DTC. Shares of common stock that are held by financial institutions as nominees for beneficial owners or in &#8220;street name&#8221; are deposited into participant accounts at DTC and are considered to be held of record by
Cede&nbsp;&amp; Co. as one stockholder. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx19490_8"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not expect to pay any cash dividends to our stockholders in the foreseeable future. Payment of future cash dividends, if any, will be at the discretion
of our board of directors and will depend on a number of factors, including our results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law, and other factors our board of directors
deems relevant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx19490_9"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The sale of our common stock to the Selling Stockholder pursuant to the Purchase Agreement will have a dilutive impact on our stockholders. In addition, the
lower our stock price is at the time we exercise our right to sell shares to the Selling Stockholder, the more shares of our common stock we will have to issue to the Selling Stockholder pursuant to the Purchase Agreement, and our existing
stockholders would experience greater dilution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After giving effect to (i)&nbsp;the sale of up to 247,840 shares of our common stock to the Selling
Stockholder pursuant to the Purchase Agreement at an assumed sale price of $3.07&nbsp;per share of our common stock and (ii)&nbsp;the issuance of an additional 79,900 shares of our common stock upon the exercise of warrants at $4.00 per share, and
after deducting estimated offering expenses payable by us, our <FONT STYLE="white-space:nowrap">as-adjusted</FONT> net tangible book value as of June&nbsp;30, 2025 would have been approximately $4.7 million, or $1.79 per share. This represents an
immediate increase in net tangible book value of $0.21 per share to existing stockholders and an immediate dilution of $1.28 per share to new investors. The table below illustrates this per share dilution: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value per share as of June&nbsp;30, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase per share attributable to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding immediately after this offering in the table above is based on
2,321,829 shares of our common stock outstanding as of June&nbsp;30, 2025, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">136,327 shares of Common Stock issuable upon the exercise of outstanding warrants to purchase our Common Stock,
with a weighted average exercise price of $7.52 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">55,455&nbsp;shares of Common Stock issuable upon exercise of outstanding stock options under our equity incentive
plan, with a weighted average exercise price of $92.21 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">217,390 shares of Common Stock issuable upon the conversion of the
<FONT STYLE="white-space:nowrap">Company&#8217;s&nbsp;Series&nbsp;A-1&nbsp;Convertible</FONT> Preferred Stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">227,170 shares of Common Stock issuable upon the conversion of the
<FONT STYLE="white-space:nowrap">Company&#8217;s&nbsp;Series&nbsp;A-2&nbsp;Convertible</FONT> Preferred Stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise
indicated, all information in this prospectus assumes no exercise of the <FONT STYLE="white-space:nowrap">outstanding&nbsp;Series&nbsp;A-1&nbsp;and</FONT> <FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Convertible</FONT> Preferred Stock,
stock options or warrants described above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx19490_10"></A>SELLING STOCKHOLDER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus relates to the possible resale from time to time by Mast Hill of any or all of the shares of our common stock that have been or may be issued
or sold by us to Mast Hill under the Purchase Agreement and an additional 79,900 shares of our common stock, upon the exercise of the Warrant. All such shares of common stock that are being registered under the Securities Act for resale by the
Selling Stockholder in this offering are expected to be freely tradable. The resale by the Selling Stockholder of a significant number of shares of our common stock that are registered for resale in this offering at any given time, or the perception
that these sales may occur, could cause the market price of our common stock to decline and to be highly volatile. We are filing the registration statement of which this prospectus forms a part to satisfy the registration rights granted to Mast Hill
pursuant to the provisions of the Registration Rights Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of Purchase Shares, if any, to Mast Hill under the Purchase Agreement will depend
upon market conditions, the trading price of the common stock, determinations by us as to the appropriate sources of funding for our operations, and other factors to be determined by us. We may ultimately decide to sell Mast Hill all, some, or none
of the Purchase Shares that may be available for us to sell to Mast Hill pursuant to the Purchase Agreement. If and when we do elect to sell Purchase Shares to Mast Hill, Mast Hill may resell all, some, or none of those shares at any time or from
time to time in its discretion, and such resales may be at different prices. As a result, investors who purchase shares of our common stock from Mast Hill in this offering at different times will likely pay different prices for those shares, and so
may experience different levels of dilution and different outcomes in their investment results. Investors may experience a decline in the value of the shares of our common stock they purchase from Mast Hill as a result of future sales made by us to
Mast Hill at prices lower than the prices such investors paid for their shares of our common stock in this offering. In addition, if we sell a substantial number of Purchase Shares to Mast Hill, or if investors expect that we will do so, the actual
sales of those shares, or the mere existence of our arrangement with Mast Hill, may make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect such sales.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although the Purchase Agreement provides that we may sell up to an aggregate of $25,000,000 of Purchase Shares to Mast Hill, only 327,740 shares of our
common stock (representing the maximum number of shares we may issue and sell under the Exchange Cap limitation) are being registered for resale under this prospectus, which includes the 79,900 Warrant Shares. If, after the Commencement Date, we
elect to issue and sell to Mast Hill all shares of common stock being registered for resale under this prospectus, the actual gross proceeds from the sale of all such shares may be substantially less than the $25,000,000 available to us under the
Purchase Agreement, depending on the market prices of our common stock during each applicable Valuation Period. If it becomes necessary for us to issue and sell to Mast Hill more shares than are being registered for resale under this prospectus in
order to receive aggregate gross proceeds equal to $25,000,000, we must first obtain stockholder approval to issue shares of common stock in excess of the Exchange Cap in accordance with applicable Nasdaq rules or find an exception to the
requirement. The number of shares of our common stock ultimately offered for sale by Mast Hill is dependent upon the number of Purchase Shares, if any, we ultimately sell to Mast Hill under the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below presents information regarding the Selling Stockholder and the shares of common stock that it may from time to time offer for resale under
this prospectus. The table is prepared based on information supplied to us by the Selling Stockholder, and reflects its holdings as of October&nbsp;[*], 2025. The number of shares in the column &#8220;Maximum Number of Shares of Common Stock to be
Offered Pursuant to this Prospectus&#8221; represents all of the shares of common stock that the Selling Stockholders may offer for resale under this prospectus, and is comprised of the Warrant Shares upon exercise of the Warrant we have issued to
Mast Hill, the additional shares of Common Stock we may sell to Mast Hill from time to time as Purchase Shares under the Purchase Agreement, subject to the Exchange Cap limitation. The Selling Stockholder may sell some, all or none of the shares it
receives in this offering. We do not know how long the Selling Stockholder will hold the shares before selling them, and we currently have no agreements, arrangements or understandings with the Selling Stockholder regarding the sale of any of the
shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with
<FONT STYLE="white-space:nowrap">Rule&nbsp;13d-3(d)&nbsp;promulgated</FONT> by the SEC under the Exchange Act, and includes shares of our common stock with respect to which the Selling Stockholder has voting and investment power. Because the
purchase price of the shares of common stock issuable under the Purchase Agreement is determined on the date of each Put Notice, the number of shares that we may actually sell under the Purchase Agreement may be fewer than the number of shares being
offered by this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Name of Selling</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares&nbsp;of<BR>Common Stock <BR>Owned <BR>Prior to Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum&nbsp;Number&nbsp;of&nbsp;Shares<BR>of Common</B><br><B>Stock to be</B><br><B>Offered</B><br><B>Pursuant
to</B><br><B>this</B><br><B>Prospectus (1)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of Shares of <BR>Common Stock Owned <BR>After Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Percent(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mast Hill Fund, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">327,740&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">327,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.37</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents all of the shares of common stock that the Selling Stockholder may offer for resale under this
prospectus, and is comprised of the Warrant Shares upon exercise of the Warrant we have issued to Mast Hill, the additional shares of common stock we may sell to Mast Hill from time to time as Purchase Shares under the Purchase Agreement, subject to
the Exchange Cap limitation. The amounts set forth in this column do not reflect the application of the Beneficial Ownership Limitation. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes the issuance and sale of all shares of our common stock being offered for resale pursuant to this
prospectus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Applicable percentage ownership is based 2,321,829 shares of our common stock outstanding as of
October&nbsp;20, 2025; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of the Warrant Shares upon exercise of the Warrant we issued to Mast Hill on May&nbsp;19, 2025, as
well as the maximum number of Purchase Shares we may sell to Mast Hill pursuant to the Purchase Agreement under the Exchange Cap limitation. The Purchase Agreement also prohibits us from issuing and selling any Purchase Shares to Mast Hill to the
extent such shares, when aggregated with all other shares of our common stock then beneficially owned by Mast Hill, would cause Mast Hill&#8217;s beneficial ownership of our common stock to exceed the Beneficial Ownership Limitation. The Purchase
Agreement also prohibits us from issuing or selling more than 327,740 shares of our common stock under the Purchase Agreement, including warrants, without obtaining stockholder approval to issue additional shares in accordance with&nbsp;applicable
rules of The Nasdaq Capital Market. The business address of Mast Hill Fund, L.P. is 150&nbsp;Grossman Dr, Suite 205, Braintree, MA 02184. Lane Murphy and Patrick Hassani have voting control and investment discretion of shares held by Mast Hill Fund,
LP by way of Mast Hill Management, LLC, the fund manager. As a result, Lane Murphy and Patrick Hassani may be deemed to have beneficial ownership (as determined under Section&nbsp;13(d) of the Securities Exchange Act of 1934, as amended (the
&#8220;Exchange Act&#8221;) of the securities reported herein that are held by Hudson. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx19490_11"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following is a summary of the material terms and provisions of our common stock and preferred stock. This summary is subject to and qualified in its
entirety by our Third Amended and Restated Certificate of Incorporation, as amended, or our certificate of incorporation, our Amended and Restated Bylaws, as amended, or our bylaws, the
<FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Certificate</FONT> of Designation and the <FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Certificate</FONT> of Designation, copies of which are included as exhibits to the registration
statement of which this prospectus forms a part, and certain provisions of Delaware law. Prospective investors should carefully review the terms and provisions of our certificate of incorporation, our Bylaws, the
<FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Certificate</FONT> of Designation and the <FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Certificate</FONT> of Designation. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, our
authorized capital stock consists of 80,000,000 shares, comprised of 50,000,000 shares of common stock, par value $0.001 per share, and 30,000,000 shares of preferred stock, par value $0.001 per share. As of October&nbsp;20, 2025, there were
2,321,829 shares of common stock, 500 shares of <FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock and 850 shares of <FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT> Stock issued and outstanding. Our
common stock is traded on the Nasdaq Capital Market under the symbol &#8220;TCRT&#8221;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Voting Rights.&nbsp;The holders of our common stock are entitled to one vote for each outstanding share of common stock owned by such stockholder on every
matter properly submitted to the stockholders for their vote. Stockholders are not entitled to vote cumulatively for the election of directors. Because of this, the holders of a majority of the shares of common stock entitled to vote in any election
of directors can elect all of the directors standing for election, if they should so choose. At any meeting of the stockholders, a quorum as to any matter shall consist of the holders of a majority of the votes entitled to be cast on the matter,
except where a larger quorum is required by law, by our certificate of incorporation or by our bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividend Rights.&nbsp;Holders of our common stock
are entitled to receive ratably dividends and other distributions of cash or any other right or property as may be declared by our Board out of our assets or funds legally available for such dividends or distributions. The dividend rights of holders
of common stock are subject to the dividend rights of the holders of any series of preferred stock that may be issued and outstanding from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Liquidation Rights.&nbsp;In the event of any voluntary or involuntary liquidation, dissolution or winding up of our affairs, holders of our common stock would
be entitled to share ratably in our assets that are legally available for distribution to stockholders after payment of liabilities. If we have any preferred stock outstanding at such time, the holders of such preferred stock may be entitled to
distribution and/or liquidation preferences that require us to pay the applicable distribution to the holders of preferred stock before paying distributions to the holders of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rights and Preferences.&nbsp;Holders of our common stock have no preemptive, conversion or subscription rights, and there are no redemption or sinking fund
provisions applicable to our common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is Equiniti Group. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See &#8220;Certain Provisions of Delaware Law, the Certificate of Incorporation and Bylaws&#8221; for a description of provisions in our certificate of
incorporation and bylaws which may have the effect of delaying, deferring or preventing changes in control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our certificate of incorporation, our Board has the authority, without stockholder approval, subject to limitations prescribed by law, to provide
for the issuance of up to 30,000,000 shares of preferred stock in one or more series, and by filing a certificate pursuant to the applicable law of the State of Delaware, to establish from time to time the number of shares to be included in each
such series, and to fix the designation, powers, preferences and rights of the shares of each series and any qualifications, limitations or restrictions thereof, and to increase or decrease the number of shares of any such series, but not below the
number of shares of such series then outstanding. We have designated 250,000 shares of our preferred stock as our Series 1 Preferred Stock, none of which are outstanding, 1,000 shares of our preferred stock as our
<FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock, 500 shares of which are outstanding, and 1,000 shares of our preferred stock as our <FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT> Stock, 850
shares of which are outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors may authorize preferred shares of stock and to divide the authorized shares of our preferred
stock into one or more series, each of which must be so designated as to distinguish the shares of each series of preferred stock from the shares of all other series and classes. Our board of directors is authorized, within any limitations
prescribed by law and our certificate of incorporation, to fix and determine the designations, rights, qualifications, preferences, limitations and terms of the shares of any series of preferred stock including, but not limited to, the following:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title and stated value; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares offered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the liquidation preference per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dividend rate(s), period(s) and/or payment date(s) or method(s) of calculation for dividends;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether dividends are
<FONT STYLE="white-space:nowrap">cumulative&nbsp;or&nbsp;non-cumulative&nbsp;and,&nbsp;if</FONT> cumulative, the date from which dividends will accumulate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right, if any, to defer payment of dividends and the maximum length of any such deferral period;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the procedures for any auction and remarketing, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions for a sinking fund, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provision for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those
redemption and repurchase rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any listing of the preferred stock on any securities exchange or market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions, if applicable, upon which the preferred stock will be convertible into common stock,
including the conversion price (or manner of calculation) and conversion period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price, or
how it will be calculated, and the exchange period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting rights, if any, of the preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preemptive rights, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on transfer, sale or other assignment, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether interests in the preferred stock will be represented by depositary shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of any material and/or special U.S. federal income tax considerations applicable to the preferred
stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the relative ranking and preferences of the preferred stock as to dividend rights and rights upon the
liquidation, dissolution or winding up of our affairs; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limitations on issuance of any class or series of preferred stock ranking senior to or on a parity with the
class or series of preferred stock as to dividend rights and rights upon liquidation, dissolution or winding up of our affairs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights, limitations or restrictions of the preferred stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board could authorize the issuance of shares of preferred stock with terms and conditions that could have the effect of
discouraging a takeover or other transaction that might involve a premium price for holders of the shares or which holders might believe to be in their best interests. The issuance of preferred stock could adversely affect the voting power,
conversion or other rights of holders of common stock and reduce the likelihood that common stockholders will receive dividend payments and payments upon liquidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The laws of the state of Delaware, the state of our incorporation, provide that the holders of preferred stock will have the right to vote separately as a
class on any proposal involving fundamental changes in the rights of holders of such preferred stock. This right is in addition to any voting rights that may be provided for in the applicable certificate of designation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;11, 2025, the Company entered into
the <FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Subscription</FONT> Agreement, by and among the Company and Water Mill, pursuant to which the Company agreed to issue and sell, in a private offering to Water Mill, shares of the <FONT
STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock, at a price per share of $1,000 for an aggregate purchase price of $500,000. The Preferred Offering also relates to the offering of the
<FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Conversion</FONT> Shares issuable upon the conversion of or otherwise pursuant to the terms of the <FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock. The <FONT
STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Offering closed on April&nbsp;11, 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares of our
<FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock, when issued or paid as a dividend, and our common stock issuable upon conversion of or otherwise pursuant to the terms of the
<FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock, will be fully paid and nonassessable. The holders of the <FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock will have no preemptive or
preferential rights to purchase or subscribe for any class of our stock, obligations, warrants or other securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividends </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of shares of issued and outstanding <FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock are entitled to receive, whether or
not declared by our Board and whether or not there are funds legally available for the payment of dividends, cumulative dividends accrued on a daily basis in arrears at the rate of 10% per annum per share on the sum of the <FONT
STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Stated</FONT> Value (as defined below) thereof plus all unpaid accrued and accumulated dividends thereon; provided, that to the extent not paid on the last day of March, June, September, and December
of each calendar year (each, a <FONT STYLE="white-space:nowrap">&#8220;Series&nbsp;A-1&nbsp;Dividend</FONT> Payment Date&#8221;), all accrued dividends on any share of <FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock
shall accumulate and compound on the applicable <FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Dividend</FONT> Payment Date whether or not declared by the Board and shall remain accumulated, compounding dividends until paid pursuant thereto
or conversion of the <FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock. The initial stated value per share (the <FONT STYLE="white-space:nowrap">&#8220;Series&nbsp;A-1&nbsp;Stated</FONT> Value&#8221;) shall be $1,000,
subject to appropriate adjustment in the event of stock splits, stock dividends, recapitalizations, or similar transaction with respect to the <FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock. Dividends will be payable in
kind through the issuance of additional shares of <FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the holders
of <FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock, to the extent any other dividends or distributions are declared for holders of the common stock, the holders of
<FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock will be entitled to participate in such dividends or distributions on <FONT STYLE="white-space:nowrap">an&nbsp;as-converted&nbsp;basis,</FONT> subject to certain
limitations set forth in <FONT STYLE="white-space:nowrap">the&nbsp;Series&nbsp;A-1&nbsp;Certificate</FONT> of Designation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon any liquidation, dissolution <FONT STYLE="white-space:nowrap">or&nbsp;winding-up&nbsp;of</FONT> the Company, whether voluntary or involuntary, or certain
deemed liquidation events, the holders of the <FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock will be entitled to receive out of our assets, an amount equal to the aggregate
<FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Stated</FONT> Value of all shares of <FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock held by such holder, plus all unpaid accrued and accumulated dividends on all
such shares of <FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock (whether or not declared), before any distribution or payment shall be made to the holders of the common stock and any other class of securities that is
specifically designated as junior to the <FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock, and if the our assets shall be insufficient to pay in full such amounts, then the entire assets to be distributed to the holders
of <FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock shall be ratably distributed among the holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in
full. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voting Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of <FONT
STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock are entitled to vote alongside holders of common stock on <FONT STYLE="white-space:nowrap">an&nbsp;as-converted&nbsp;basis</FONT> on a 1:1 ratio as common stock, voting together
as a single class, with respect to any and all matters presented to the stockholders of the Company for their action; provided, however, that, except as otherwise required by law, holders of common stock, as such, shall not be entitled to vote on
any amendment to the <FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Certificate</FONT> of Designation. In any such vote, each holder of <FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock shall be entitled to a number
of votes equal to the number of shares of common stock into which such holder&#8217;s shares of <FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock are convertible pursuant to the
<FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Certificate</FONT> of Designation as of the record date of such vote or written consent (or as otherwise required by applicable law). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conversions </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the provisions of the <FONT
STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Certificate</FONT> of Designation, the holder of <FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock may, at its option, at any time and from time to time, convert all or any
portion of outstanding shares <FONT STYLE="white-space:nowrap">of&nbsp;Series&nbsp;A-1&nbsp;Preferred</FONT> Stock then held by such holder, along with the aggregate accrued or accumulated and unpaid dividends thereon, into shares of common stock.
Each share of <FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock is convertible into such number of shares of common stock equal to (i)&nbsp;the sum of the <FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Stated</FONT>
Value plus all accrued and accumulated and unpaid dividends thereon, divided by (ii)&nbsp;the conversion price in effect immediately prior to&nbsp;such conversion. The initial conversion price per share of
<FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock shall be $2.76. The conversion price is subject to adjustment in the event of (a)&nbsp;payment of dividend or other distribution upon the common stock or any other capital
stock of the Company payable in shares of common stock or in options or convertible securities of the Company, (b)&nbsp;subdivision or combination of the Company&#8217;s outstanding shares of common stock, or (c)&nbsp;reorganization,
reclassification, consolidation, or merger involving the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, each share of
<FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock shall automatically convert into fully paid and nonassessable shares of the common stock, at the conversion price, without any action required by the holder of the <FONT
STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock, upon the occurrence of a Change of Control (as defined in <FONT STYLE="white-space:nowrap">the&nbsp;Series&nbsp;A-1&nbsp;Certificate</FONT> of Designation). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Limitations on Conversion </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No party may convert any
shares of <FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock or otherwise issue shares on account of such shares of <FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock if, as a result of the
conversion or issuance, a holder and its affiliates would beneficially own in excess of 4.99% of the shares of our common stock. However, upon 61 days&#8217; advance notice to us, a holder may increase the limit of beneficially owned shares of our
common stock from 4.99% to any amount up 9.99% of the shares of our common stock. In the event that the issuance of shares of Common Stock to a holder upon conversion of, or otherwise on account, the shares of
<FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock results in such holder and its affiliates being deemed to beneficially own, in the aggregate, more than the maximum percentage described in the preceding sentence of the
number of outstanding shares of our Common Stock (as determined </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under Section&nbsp;13(d) of the Exchange Act), the number of shares so issued by which the holder&#8217;s and its affiliates&#8217; aggregate beneficial ownership exceeds such maximum percentage
will be deemed null and void and will be cancelled ab initio, and the holder will not have the power to vote or to transfer such excess shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exchange Listing </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no established public trading
market for the <FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock, and we do not expect a market to develop. In addition, we do not intend to list the <FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT>
Stock on any securities exchange or nationally recognized trading system. Without an active trading market, the liquidity of the <FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT> Stock will be limited. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT> Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;24, 2025, the Company entered into
the <FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Subscription</FONT> Agreement, by and among the Company and the Buyers, pursuant to which the Company agreed to issue and sell, in a private offering to the Buyers, shares of the <FONT
STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT> Stock, at a price per share of $1,000 for an aggregate purchase price of $850,000. The Preferred Offering also relates to the offering of the
<FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Conversion</FONT> Shares issuable upon the conversion of or otherwise pursuant to the terms of the <FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT> Stock. The <FONT
STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT> Offering closed on June&nbsp;24, 2025. The shares of our <FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT> Stock, when issued or paid as a dividend, and our common
stock issuable upon conversion of or otherwise pursuant to the terms of the <FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT> Stock, will be fully paid and nonassessable. The holders of the
<FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT> Stock will have no preemptive or preferential rights to purchase or subscribe for any class of our stock, obligations, warrants or other securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividends </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of shares of issued and outstanding <FONT
STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT> Stock are entitled to receive, whether or not declared by our Board and whether or not there are funds legally available for the payment of dividends, cumulative dividends accrued on a
daily basis in arrears at the rate of 10% per annum per share on the sum of the Stated Value (as defined below) thereof plus all unpaid accrued and accumulated dividends thereon; provided, that to the extent not paid on the last day of March, June,
September, and December of each calendar year (each, a <FONT STYLE="white-space:nowrap">&#8220;Series&nbsp;A-2&nbsp;Dividend</FONT> Payment Date&#8221;), all accrued dividends on any share of
<FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT> Stock shall accumulate and compound on the applicable <FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Dividend</FONT> Payment Date whether or not declared by the Board and
shall remain accumulated, compounding dividends until paid pursuant thereto or conversion of the <FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT> Stock. The initial stated value per share (the &#8220;Stated Value&#8221;) shall
be $1,000, subject to appropriate adjustment in the event of stock splits, stock dividends, recapitalizations, or similar transaction with respect to the <FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT> Stock. Dividends will be
payable in kind through the issuance of additional shares of <FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT> Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition,
the holders of <FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT> Stock, to the extent any other dividends or distributions are declared for holders of the common stock, the holders of
<FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT> Stock will be entitled to participate in such dividends or distributions on <FONT STYLE="white-space:nowrap">an&nbsp;as-converted&nbsp;basis,</FONT> subject to certain
limitations set forth in <FONT STYLE="white-space:nowrap">the&nbsp;Series&nbsp;A-2&nbsp;Certificate</FONT> of Designation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon any liquidation, dissolution <FONT STYLE="white-space:nowrap">or&nbsp;winding-up&nbsp;of</FONT> the Company, whether voluntary or involuntary, or certain
deemed liquidation events, the holders of the <FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT> Stock will be entitled to receive out of our assets, an amount equal to the aggregate
<FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Stated</FONT> Value of all shares of <FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT> Stock held by such holder, plus all unpaid accrued and accumulated dividends on all
such shares of <FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stock (whether or not declared), before any distribution or payment shall be made to the holders of the common stock and any other class of securities that is specifically designated as junior to
the <FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT> Stock, and if the our assets shall be insufficient to pay in full such amounts, then the entire assets to be distributed to the holders of
<FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT> Stock shall be ratably distributed among the holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in
full. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voting Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of <FONT
STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT> Stock are entitled to vote alongside holders of common stock on <FONT STYLE="white-space:nowrap">an&nbsp;as-converted&nbsp;basis</FONT> on a 1:1 ratio as common stock, voting together
as a single class, with respect to any and all matters presented to the stockholders of the Company for their action; provided, however, that, except as otherwise required by law, holders of common stock, as such, shall not be entitled to vote on
any amendment to the <FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Certificate</FONT> of Designation. In any such vote, each holder of <FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT> Stock shall be entitled to a number
of votes equal to the number of shares of common stock into which such holder&#8217;s shares of <FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT> Stock are convertible pursuant to the
<FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Certificate</FONT> of Designation as of the record date of such vote or written consent (or as otherwise required by applicable law). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conversions </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the provisions of the <FONT
STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Certificate</FONT> of Designation, the holder of <FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT> Stock may, at its option, at any time and from time to time, convert all or any
portion of outstanding shares <FONT STYLE="white-space:nowrap">of&nbsp;Series&nbsp;A-2&nbsp;Preferred</FONT> Stock then held by such holder, along with the aggregate accrued or accumulated and unpaid dividends thereon, into shares of common stock.
Each share of <FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT> Stock is convertible into such number of shares of common stock equal to (i)&nbsp;the sum of the <FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Stated</FONT>
Value plus all accrued and accumulated and unpaid dividends thereon, divided by (ii)&nbsp;the conversion price in effect immediately prior to such conversion. The initial conversion price per share of
<FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT> Stock shall be $4.49. The conversion price is subject to adjustment in the event of (a)&nbsp;payment of dividend or other distribution upon the common stock or any other capital
stock of the Company payable in shares of common stock or in options or convertible securities of the Company, (b)&nbsp;subdivision or combination of the Company&#8217;s outstanding shares of common stock, or (c)&nbsp;reorganization,
reclassification, consolidation, or merger involving the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, each share of
<FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT> Stock shall automatically convert into fully paid and nonassessable shares of the common stock, at the conversion price, without any action required by the holder of the <FONT
STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT> Stock, upon the occurrence of a Change of Control (as defined in the <FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Certificate</FONT> of Designation). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exchange Listing </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no established public trading
market for the <FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT> Stock, and we do not expect a market to develop. In addition, we do not intend to list the <FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT>
Stock on any securities exchange or nationally recognized trading system. Without an active trading market, the liquidity of the <FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT> Stock will be limited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx19490_12"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The common stock offered by this prospectus are being offered by the Selling Stockholder. The shares may be sold or distributed from time to time by the
Selling Stockholder directly to one or more purchasers or through brokers, dealers, or underwriters who may act solely as agents at market prices prevailing at the time of sale, at prices related to the prevailing market prices, at negotiated
prices, or at fixed prices, which may be changed. The sale of our common stock offered by this prospectus could be effected in one or more of the following methods: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokers&#8217; transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transactions involving cross or block trades; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through brokers, dealers, or underwriters who may act solely as agents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;at the market&#8221; into an existing market for our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in other ways not involving market makers or established business markets, including direct sales to purchasers
or sales effected through agents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in privately negotiated transactions; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any combination of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholder may also sell shares of common stock under Rule 144 promulgated under the Securities Act, if available, rather than under this
prospectus. In addition, the Selling Stockholder may transfer the shares of common stock by other means not described in this prospectus. If the Selling Stockholder effects such transactions by selling shares of common stock to or through
underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from the Selling Stockholders or commissions from purchasers of the shares of common
stock for whom they may act as agent or to whom they may sell as principal (which discounts, concessions or commissions as to particular underwriters, broker-dealers or agents may be in excess of those customary in the types of transactions
involved). In connection with sales of the shares of common stock or otherwise, the Selling Stockholder may enter into hedging transactions with broker-dealers, which may in turn engage in short sales of the shares of common stock in the course of
hedging in positions they assume. If the Company elects to waive, in whole or in part, the restrictions on short sales by the Selling Stockholder in the Purchase Agreement, the Selling Stockholders would be permitted to also sell shares of common
stock short and deliver shares of common stock, as applicable, covered by this prospectus to close out short positions and to return borrowed shares in connection with such short sales. The Selling Stockholder may also loan or pledge shares of
common stock to broker-dealers that in turn may sell such shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholder may pledge or grant a security interest in securities owned by
them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock from time to time pursuant to this prospectus or any amendment to this prospectus under
Rule&nbsp;424(b)(3) or other applicable provision of the Securities Act amending, if necessary, the list of Selling Stockholder to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus. The
Selling Stockholder also may transfer and donate the shares of common stock in other circumstances in which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the securities laws of some states, the shares of common stock may be sold in such states only through registered or licensed brokers or dealers.
In addition, in some states the shares of common stock may not be sold unless such shares have been registered or qualified for sale in such state or an exemption from registration or qualification is available and is complied with. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that the Selling Stockholder will sell any or all of the shares of common stock registered pursuant to the registration statement,
of which this prospectus forms a part. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholder, Mast Hill, is an &#8220;underwriter&#8221; within the meaning of
Section&nbsp;2(a)(11) of the Securities Act. As an underwriter, Mast Hill is required to comply with certain requirements of the Securities Act and the Exchange Act, including Regulation M. With certain exceptions, Regulation M precludes Mast Hill,
any affiliated purchasers, and any broker-dealer or other person who participates in the distribution, from bidding for or purchasing, or attempting to induce any person to bid for or purchase, any security that is the subject of the distribution
until the entire distribution is complete. Regulation M also prohibits any bids or purchases made in order to stabilize the price of a security in connection with the distribution of that security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as disclosed in this prospectus, we know of no existing arrangements between Mast Hill or any other stockholder, broker, dealer, underwriter or agent
relating to the sale or distribution of the shares of our common stock offered by this prospectus. Mast Hill has informed us that it intends to use one or more registered broker-dealers to effectuate all sales, if any, of our common stock that it
has acquired and may in the future acquire from us pursuant to the Purchase Agreement. Each such registered broker-dealer will be an underwriter within the meaning of Section&nbsp;2(a)(11) of the Securities Act. Mast Hill has informed us that each
such broker-dealer will receive commissions from Mast Hill that will not exceed customary brokerage commissions. Except as disclosed in this prospectus, we know of no existing arrangements between Mast Hill or any other stockholder, broker, dealer,
underwriter or agent relating to the sale or distribution of the shares of our common stock offered by this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent required by
the&nbsp;Securities Act&nbsp;and the rules and regulations thereunder, any broker-dealer participating in the distribution of the shares of common stock may be deemed to be &#8220;underwriters&#8221; within the meaning of the&nbsp;Securities Act,
and any commission paid, or any discounts or concessions allowed to, any such broker-dealer may be deemed to be underwriting commissions or discounts under the&nbsp;Securities Act. At the time a particular offering of the shares of common stock is
made, a prospectus supplement, if required, will be distributed, which will set forth the aggregate amount of shares of common stock being offered and the terms of the offering, including the name or names of any broker-dealers or agents, any
discounts, commissions and other terms constituting compensation from the selling stockholders and any discounts, commissions or concessions allowed <FONT STYLE="white-space:nowrap">or&nbsp;re-allowed&nbsp;or</FONT> paid to broker-dealers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholders and any other person participating in distribution of the shares of common stock will be subject to applicable provisions of the
Securities Exchange, and the rules and regulations thereunder, including, without limitation, to the extent applicable, Regulation M of the Exchange Act, which may limit the timing of purchases and sales of any of the shares of common stock by the
Selling Stockholders and any other participating person. To the extent applicable, Regulation M may also restrict the ability of any person engaged in the distribution of the shares of common stock to engage in market-making activities with respect
to the shares of common stock. All of the foregoing may affect the marketability of the common stock and the ability of any person or entity to engage in market-making activities with respect to the shares of common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx19490_13"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the issuance of our common stock offered in this prospectus will be passed upon for us by The Doney Law Firm, Las Vegas, Nevada. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx19490_14"></A>EXPERTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
financial statements of Alaunos Therapeutics, Inc. as of and for the year ended December 31, 2024, incorporated in this prospectus by reference from our Annual Report on Form 10-K as of and for the year ended December 31, 2024, have been audited,
along with the adjustments described in Note 3 therein which were applied retroactively to reflect the July 2024 one-for-ten reverse stock split in the 2023 financial statements as of and for the year ended December 31, 2023, audited by Cherry
Bekaert LLP, an independent registered public accounting firm, as set forth in their report thereon (which report expresses an unqualified opinion and includes an explanatory paragraph relating to the entity&#8217;s ability to continue as a going
concern), and have been incorporated in this prospectus and registration statement in reliance upon the report of such firm given their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements of Alaunos Therapeutics, Inc. as of and for the year ended December&nbsp;31, 2023, incorporated in this Prospectus by reference from
our Annual Report on Form 10-K for the year ended December&nbsp;31, 2024, have been audited, except for the adjustments to retroactively apply the July 2024 one-for-ten reverse stock split in the 2023 financial statements, by RSM US LLP, an
independent registered public accounting firm, as stated in their report thereon (which report expresses an unqualified opinion and includes an explanatory paragraph relating to the entity&#8217;s ability to continue as a going concern) incorporated
herein by reference, and have been incorporated in this Prospectus and Registration Statement in reliance upon such report and upon the authority of such firm as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx19490_15"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is registered with the SEC under Section&nbsp;12 of the Exchange Act and, accordingly, we are subject to the information and periodic
reporting requirements of the Exchange Act, and we file periodic reports, proxy statements and other information with the SEC. These periodic reports, proxy statements and other information are available at the website of the SEC at www.sec.gov.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain a website at www.alaunos.com. You may access our Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on
Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and amendments to those reports, proxy statements and other information filed or furnished pursuant to Section&nbsp;13(a) or 15(d)
of the Exchange Act with the SEC free of charge at our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. We have not incorporated by reference into this prospectus or any
accompanying prospectus supplement the information on our website, and you should not consider it to be a part of this prospectus or any accompanying prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement under the Securities Act, relating to the securities being offering by the Selling Stockholder. The
registration statement, including the attached exhibits, contains additional relevant information about us and the securities. This prospectus does not contain all of the information set forth in the registration statement. You can obtain a copy of
the registration statement for free at the website of the SEC referenced above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx19490_16"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#8220;incorporate by reference&#8221; information that we file with them. Incorporation by reference allows us to disclose important
information to you by referring you to those other documents. The information incorporated by reference is an important part of this prospectus, and information that we file later with the SEC will automatically update and supersede this
information. This prospectus omits certain information contained in the registration statement, as permitted by the SEC. You should refer to the registration statement, including the exhibits, for further information about us and the securities we
may offer pursuant to this prospectus. Statements in this prospectus regarding the provisions of certain documents filed with, or incorporated by reference in, the registration statement are not necessarily complete and each statement is qualified
in all respects by that reference. Copies of all or any part of the registration statement, including the documents incorporated by reference or the exhibits, may be obtained upon payment of the prescribed rates at the offices of the SEC listed
above in &#8220;Where You Can Find More Information.&#8221; The following documents filed by us with the Commission are incorporated by reference in this prospectus: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1107421/000095017025047758/tcrt-20241231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December 31, 2024, filed with the SEC on March 31, 2025, as amended on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1107421/000095017025061207/tcrt-20241231.htm">April
 30, 2025</A>; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Qs</FONT> for the quarter ended March 31, 2025,
filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1107421/000095017025072709/tcrt-20250331.htm">May&nbsp;
15, 2025</A>, for the quarter ended June 30, 2025, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1107421/000095017025108887/tcrt-20250630.htm">August&nbsp;14, 2025</A>, and for the quarter
ended September&nbsp;30, 2025, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001107421/000119312525282988/tcrt-20250930.htm">November&nbsp;14, 2025</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1107421/000095017025053325/tcrt-20250407.htm">April
 11, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1107421/000095017025053523/tcrt-20250411.htm">April 14, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1107421/000095017025054309/tcrt-20250415.htm">April
 15, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1107421/000095017025055903/tcrt-20250415.htm">April 18, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1107421/000095017025077064/tcrt-20250519.htm">May
 23, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1107421/000095017025083913/tcrt-20250609.htm">June 10, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1107421/000095017025090201/tcrt-20250624.htm">June
 26, 2025</A>/<A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1107421/000095017025090202/tcrt-20250620.htm">June 26, 2025</A> (two reports), <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1107421/000095017025093263/tcrt-20250701.htm">July
 2, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1107421/000095017025095029/tcrt-20250703.htm">July 10, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1107421/000095017025096656/tcrt-20250715.htm">July
 17, 2025</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1107421/000095017025097591/tcrt-20250716.htm">July 22, 2025</A>, to the extent the information in such reports is filed and not furnished; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock set forth in <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-ex4_7.htm">Exhibit
 4.7</A> to our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;for</FONT> the fiscal year ended December&nbsp;31, 2021, which was filed with the SEC on March&nbsp;30, 2022, including any amendment or reports filed for the
purposes of updating this description. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also incorporate by reference all documents we file pursuant to Section&nbsp;13(a), 13(c), 14
or 15 of the Exchange Act (other than any portions of filings that are furnished rather than filed pursuant to Items 2.02 and 7.01 of a Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K)&nbsp;after</FONT> the date of the initial
registration statement of which this prospectus is a part and prior to effectiveness of such registration statement. All documents we file in the future pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this
prospectus and prior to the termination of the offering are also incorporated herein by reference and are an important part of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any
statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this registration statement to the extent that a statement contained herein or in any
other subsequently filed document which also is or deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a
part of this registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will provide upon request to each person, including any beneficial owner, to whom a prospectus is delivered, a
copy of any or all of the information that has been incorporated by reference in the prospectus but not delivered with the prospectus. You may request a copy of these filings, excluding the exhibits to such filings which we have not specifically
incorporated by reference in such filings, at no cost, by writing to or calling us at: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Alaunos Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">501 E. Las Olas Blvd., Suite 300 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fort Lauderdale, FL 33301 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="white-space:nowrap">(346)&nbsp;355-4099</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You can also find these filings on our website at www.alaunos.com. We are not incorporating the information
on our website other than these filings into this prospectus or any accompanying prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration
statement we filed with the SEC. You should only rely on the information or representations contained in this prospectus, in any accompanying prospectus supplement or any related free writing prospectus, or incorporated by reference herein or
therein. Neither we nor the Selling Stockholders have authorized anyone to provide information other than that provided in this prospectus, any accompanying prospectus supplement or any free writing prospectus we have prepared. Neither we nor the
Selling Stockholders are making an offer of the securities in any state where the offer is not permitted. You should not assume that the information in this prospectus or any prospectus supplement is accurate as of any date other than the date on
the front of the document. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g19490g03a37.jpg" ALT="LOGO" STYLE="width:3.95909in;height:0.94091in;">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Up to 327,740 Shares of Common Stock </B></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:200pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus </B></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:200pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;11, 2025 </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g19490g03a37.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g19490g03a37.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_[1@^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &"$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M @,!               !" ('! 4& __$ %40  $# P$$ P@,"@8+  ,!  $
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MV.I@<1(QP(*ZNDZB<-HWP\OU+T^O58YG7Y+,-=UX6;3S71Z3O<=[MK9V8#N
M<W/(X7=M((..2^GQWB]>Z'Y_DQSCM-+<PS18K)74$/)%!Y(.+65,='3R3SO#
M(V#+G'J58=J&TJMU%624=NEEI[8PENZUV#)QQDXZL=2V%TAM2R4-IAL],[#Z
MH[\C@<'='5Z1YE70+;'7QN6=[?4(R03GCVXZUV=FL-RO,PCMU++,2<;S6DCS
MKUNRG0+]75[Y:DOCMT)&\X#.\<\0/"K/V:T45HHVTUNIHZ>)O'=C:!Q[>"M;
M)KA6M-J\V78A?*UK7UE32TK3S!WB?4O6T&P:B8 :RZOD/6&1$>G>6Z<<?"L@
M/ LN^6D5AJZ#8EIA@'=F5$I[>ZN'VKD>XQI+_P#5G_QW?>ME (H[Y3VPU35;
M$-/2-/L=\\)[=YSOM7G[AL#80307@ ]DD) \^2M[)A1WR=L*MWC8QJ&A!=3F
MFJFC^SWL_57A[KIZZVESA7T$\./UG,.%=DM&>KS+XU-+!51.BJ(F2,<,%KAD
M%:1EE2:*+.Z^"SAFDA>'Q/<QXXAS3@CYU:'5&QZPW9SYJ(.M]01_N6#=)\7#
MUK46I-D5_M<_^B0FMIR[ >P>^P>LA:1>)Y5[9=]L7U5JJX7B*W,J'5="P9D,
MY+MQO5@X..I6+:5X?9/I%FE].0L<W_3)VA\Y+<'/$X^;/H7N0"N>^M^&E8TR
M1$4+.OOEO9=;55T,KG,941NB<YIX@$85=MIVC8-,7.T4]'65+F5;PQ^\X\B[
M':K,$<%I+;X/Z?TSY9OUU:DZE67J=):%I--4M1<:6IGDEFI-TAY.!D ]9/8M
M.;.[U4V77IK9Y)#135$M-)QX9.2!YP%9,][P^2CZJKWIZS/NVB-3F$'V127(
M5$9 ZP<'T$JU?.]HMOZ>UV_WZ2.UT5IMTCN[U+C))N.Y,#<<?&7#S+LNCO+)
M+HN0RO<\B9PRXYZRM=:8%3JMU_O]Q;AE'0MA9UC?& .?@:5L'HX]Y+_#*?64
MG7:1RVLB(LUQ$1 0\D1!&2L7<,K+K74:KNT5DL=773N [DPD9ZSA(C8T;TB-
M3"IN,%CIG>]ISORD'FXC@/6M+\",=2YEYN$UTNM575#LS5#S(X^,KDZ8L\M]
MOE);J8'?FD#<]30>975$=L,9\RWGT==.>Q+74WBI:1+4.#8RX?J@<_\ V6Z0
M."ZZR6^&UVNFHZ9N[%"P-"[(<ESVG<M:QJ <$1%5+KKY01W.UU-',,LF86'@
MJ;:NLDVG]05MNJ&D=RD=N$C&\W>.'?. KKN\:T?TB=-=UI8+Y P[\6(Y=T=7
M4?0M,=M2I:-PK^3CCD#PE6;V!:F%TTX;=,_-12' R>.Z>7J*K&1@$ <>H>%>
MOV8:F=IG5%-4EW^C2.;%-^X2,GYAE:Y*[A2DZE<3J4CDN/#*Q\;9&.#FNX@C
MBONWDN9JE$1$B(B B(@\_KKO2NOR=_U2J7/^&[QJZ.NN]*Z_)W_5*I<_X;O&
MM\+*[<'1K[X[A\G_ (@K'CX*KAT:^^.X?)_X@K'CX*SR<IQ\,F\D1O)%1H(B
M("(B B(@(B("(B B(@>%<"[5T-LH9ZNI<&PQ-WG.)Y!<T=:T;TB=5&*FBL-*
M]N91OS$'J'(>M6K&Y5GPTQJN^2Z@O=37SG\HXEHSG R3A<"@HY:^M@I8&YEE
M>UC?&3@+C=9/4MR='[2)K;B^^549]C4Y#8<_K/''/J71,]L,8CNENK0>GHM-
M:<I[?",N&7R.Q@N<>OT!>B') ."G]4KEGRWB--&](?2IFACOE*SWT>&S8'5R
M!/H6@OM5X;O;X;G;IZ2J;O12MW2/4J<:RL,NG-0U5!.#NQO)83UM.<'S86^.
MV_#.]7I=C.KSIS4;(9W?Z#5D1OR<!I)'OO0?.K7QD%N<JB,+C&YI:<$'.5:_
M8WJ8:ATM&R1[364H#)1GCUX/H*C+77E-)^FPLHL&^-9K%H(B("(B!UE8_K%9
M=96(^$4%7ND3W_-^1Q_6>M7GFMH=(GO^;\CC^L]:O/-=>/XL+<K3]'_O%B_?
M/K*V8M9]'_O%B_?/K*V8N:W+:O B(JI$1$!$1 4=94J.LH0CM6KND/WC_P#>
M;]JVCVK5W2'[Q_\ O-^U6K\H5GA6!;:Z-_?=5>16I5MKHW]]U5Y%=-_BRIRL
MN.:E0.:E<C<1$0$/)$/)!53;[^D"I\BS[5KN#\HSQA;$V^_I!J?(L^U:[A_*
M,\8753XL)Y7/TS#'/I2WQ2M#V/I@'-(SD85>ML.S^33M=)<:!CGVV5P)X8[F
MX]7BSZU8O1_>S;3_ '#?4N5=[=372AFI*R,/@E&'-*PBW;+3MW"C@X'Q=:VI
ML=VB2V"J%LN4A?;9<-87./XHYYCTKH]I^AJG25S+V,?);IG'N4F,@=>#V=?F
M7AQP\_I6\Q%H9QN)7J@E9-$R2(AT;P'-(ZPN1E5XV*;1W4;V62]3-[@X@02N
MX;G#&"?,K",<'-R""#RQUKGM74MHG;Z(@152(B((*U5TAN\]GEA]5RVJ5JKI
M#=Y[/+#ZKE:G*LJQ'X)6Y>C5WP7+R;/XEIH_!*W+T:N^"Y>39_$M[\,XY6,6
M0Y+%9#DN9L*#@*5@X\4''KZAE+32S2.#6M!)*KYJ6[/O%UEJ7'WF2&#/(96T
M]J5R]B6,0L< Z=VY\V"M+=9(Z^*\/U3/QCA];_#W2Q$3GG_XE0I'7A,+Q];?
M5(QQY97?:5TW47VHPP%M.#[]X&<+C::M$EYN45-&/>DY>X=06^;':X;7014\
M+<!K<>->CT/1^]/=;B'@>K>J?R\>WC^4N!I[3-%9H&B*,&3&"\M&2O0, Q@+
M+'#"8'S+Z"E*TC58?%Y,M\MNZ\[,*0 @QQ4J^F;XSQ,D86O (/#B%X/5N@Z>
MMCDFH!W*;&2P 8<5L'ARPL2.!ZPL<N&F6-6AT=/U63I[=V.59JZDFHZF2FJ6
M%LD9Q@\\+XA;GV@Z8;<Z)]53,Q51C(\(ZPM+N!:7 @AP.#GJXKYOJ^FG!;7T
M^[]-]0CJ\?\ F!%(X9[% 7*]27K]FUZ=;[P*=Q_$5& 03R(Y>M;QB(<W(Y*L
M=/*Z"9DL9PYIR%8K358*ZT03Y!WF@^A>[Z7FFU9I+XO^(.EC'>,L?;M5*@=H
M4KUWS@H=R4J'<D%8.D/.Z36K6$\&0C 6K!P)':MP=)&WOBU'25NZ>YSQ;N?"
M%I\<R%U4^+"W*V>Q"FBI]GM Z( .DS(_':5[YO,]JTYT>-1Q55AELTKFBII7
M;S03C>:[EZO2MQ,YE<]N6M>&:)@*.I562BA2@)E.:!!!4CDG)$!8D9SD9"R3
MJ*#%O#*R)PF$0$1$$.Y%=9=++;;I)#)<:*"I?"08W2-R6G.>"[1,(..(6=R[
MD&#N8;N[N.&.Q=?06.VVZ.>.AH8*=DYWI0QN-\GM7<8"C 3:-.HHK%;:.CEI
M*6AIX::4GND;&X#O'YURK/::&T4Q@ME)#2PDYW8F[H)[5S>"D<DVG0B(@(B(
M"(H)00XK0/2)U47S0V&ED&&XDG([<' \Q6[-0W**T6FIK:AX:R)N<GMY!4RU
M%=)KS>:NNJ'%SII'.!/4,\ M,5=SM2TNM\/5VK?'1UTQEL]\J&$<F09Z_A9/
MJ6C:6-LE1&Q[@QKG $GD K3:7U?H^PV2DM]-=J?N<# W>P[)/6>2TR;UJ%:Q
M^VQ0W@5(SCFO'^Z1I;XV@\SON0;2-*_&\'F=]RP[9:;A[#![4PO'^Z1I7XW@
M\SON3W2-*_&\'F=]R=MC</7@+K[[;(+O:YZ&J;F*5NZ<<UT VD:6^-X/,[[E
MB[:/I8C\[P>9WW)%9-QI5'4%IGLMXJK?5-(? \L\8!(SZ%UPX9QS6TMN%58[
MM<*:Y62LAFF<"V9K,YY\#Q^=:NZETUG<,)\<+1["]3B]Z8;33O!JJ5Q:1UEO
M4?6MFMY*H.R34[]-ZKIY'NQ2U#FQ2CJ )QGYLJW%+.V>%DD;@YCP' ]H*PR5
MU+:D^'W1,A%181$0$1$'G]==Z5U^3O\ JE4N?\-WC5T===Z5U^3O^J52Y_PW
M>-;X65VX.C7WQW#Y/_$%8\?!5<.C7WQW#Y/_ !!6/'P5GDY3CX9-Y(C>2*C0
M1$0$1$!$1 1$0$1$!$6)*#JM27:"RV:LKZEX9'#&3D]9ZE3?4=WGOMYJ;A5'
MW\SRX#'($DX]*V]TA]5"22.QTLO!CMZ<-/@X ^=:-'AXA=&*OVRM/TY]BMD]
MWNM/0TK"Z69P: .U7)TE9(+!8Z>W4X]Y$.)[2M0='G2(W9K]70^_R&4^^.0Q
MQ</0M[MX K/);:U*Z9 !".!4A!UK-=CC(*TWT@M*>SK,+U2QDU%.YK90WCEG
M$9QX]U;E(]Z5Q*VDBK*26FG8'QR-PX.&05-9U.T3&U&>WPA>VV2ZI?IG5$3R
MX"DJ=V*<'LSS\8X^==;M T[+IK4E71O81#ON=%^Z2<>A>;8XAV1P.<@CJ73K
MOAC'XRO;$]LD8?&0YKN((ZU]&K6FQ/5C+]IQE)42YKZ3#7@GBYO'!]!6RF'F
MN:8TVB=LD1%"1$1 ZRL1\(K+K*Q'PBH%7ND3W_-^1Q_6>M7GFMH=(GO^;\CC
M^L]:O/-=F/XL+<K3]'_O%B_?/K*V8M9]'_O%B_?/K*V8N:W+:O B(JI$1$!$
M1 4=94J.LH0=JU;TA^\?_O-^U;26K>D/WC_]YOVJU?E"L\*P+;71O[[JKR*U
M*MM=&_ONJO(KIO\ %E3E9<<U*@<U*Y&XB(@(>2(>2"JFWS](-3Y%GVK74'Y1
MGC"V+M\_2#4^19]JUU!^4;^\%U4^+">5UM'][%M\@WU+N%T^D.]BV>0;ZEW
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MO5S-LMMOT7TK'&/I:1KZ$12.8RN>(\NZUXB-[;@V46AM+:C6R#\;.XXR>3>
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M[7$X'K5.+A5RUU=/53N+I)7EY+CD\5M;I ZJ%PO/X%I'[U/2[KI' Y#GD9]
M(\RU"/&NG%74;8VD;D'//QKTE)KC45)3QP4]VJXX6-#6M9,X  <N *PI-%ZB
MJJ>.HIK+7RPR-#V2,A<0X'B"#A?7VAZI^(+C_@.^Y6F8E$;?3W0-3_'=?_CO
M^]/= U/\=U__ )#_ +U\_:'JCX@N/^ [[D]H6J/B"X_X#ON4:J;E]/= U/\
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M6J"OH9&OAE:#P(.#CD5X'I##^IS/*CZKEE7'&_*\]1:(_'PK*][GDF1Q<?\
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MHB $1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 '+BB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B!GP($1 1
M$0$1$!$1 1$0$1$!$1 ',HB("(B B(@(B((*;JE$$80!2B B(@C"@ Y62((
M3"E$$8XH I1 4 8RI1 "(B B(@(B("(B B(@(B("=2(@@!2B( 1$0$1$!$1
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M8*X4_<Y-S=+<KUXV".^-V_0_R5]5CE6)EZ<;;M-]LOT'_P J>[=IOME^@_\
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M,D[E6J2 0M$;?]%;S3J"WQ8<T?Z0&CGQP'>I;W RN/<J.&NH9Z6I8'PRL+'
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$B(/_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
